SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024

The board (the "**Board**") of directors (the "**Directors**") of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") hereby announces the unaudited condensed consolidated interim results of the Company and its subsidiaries (the "**Group**") for the six months ended 30 June 2024 (the "**Reporting Period**"), together with the comparative figures for the corresponding period in 2023. The unaudited condensed consolidated financial statements of the Group for the Reporting Period have been reviewed by the audit committee of the Company (the "**Audit Committee**") and the Company's auditors, Deloitte Touche Tohmatsu. Unless otherwise specified, figures in this announcement are prepared under the International Financial Reporting Standards ("**IFRSs**").

In this announcement, "we", "us" and "our" refer to the Company and where the context otherwise requires, the Group.

Financial Highlights

- As at 30 June 2024, total revenue of the Group was approximately RMB786 million for the Reporting Period, representing an increase of approximately 17% compared to the corresponding period in 2023, which was mainly due to the increase in revenue from pharmaceutical products by approximately 11% compared to the corresponding period in 2023, in particular: the domestic sales revenue of our core product TUOYI® (toripalimab) was approximately RMB671 million, representing an increase of approximately 50% compared to the corresponding period in 2023.

- Total research and development ("**R&D**") expenses of the Group were approximately RMB546 million for the Reporting Period, representing a decrease of approximately 42% compared to the corresponding period in 2023. The decrease in R&D expenses was mainly due to the Group's cost control policy and efforts to optimize resource allocation and focusing on R&D pipelines with greater potential. In addition, a number of clinical trials of our core product TUOYI® successively met the primary endpoints, which also contributed to natural decline of R&D expenditure.

- Loss attributable to owners of the Company decreased to RMB646 million for the Reporting Period, representing a decrease of approximately RMB351 million or approximately 35% compared to the corresponding period in 2023.

- As at 30 June 2024, the aggregate balance of bank balances and cash and financial products of the Group was approximately RMB3,311 million, slightly decreased by RMB467 million compared to the balance of 31 December 2023, which ensured our cash position relatively sufficient to support the Group's development.

Business Highlights

During the Reporting Period, focusing on the "unmet medical needs", we have made original, innovative and breakthrough progress in discovery, R&D and commercialization of innovative therapies and innovative drugs with accelerating international development. The following achievements and milestones were attained:

- Our innovative R&D field has expanded from monoclonal antibodies to the research and development of more drug modalities, including small molecules drugs, polypeptide drugs, antibody drug conjugates (ADCs), bi-specific or multi-specific antibodies and nucleic acid drugs, as well as the exploration of next-generation innovative therapies including cancer and autoimmune diseases. Our product pipelines cover five major therapeutic areas including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. A total of three drugs (TUOYI®, JUNMAIKANG (君邁康®) and MINDEWEI (民得維®)) are being commercialized, around 30 assets are undergoing clinical trials, and over 20 drug candidates are at preclinical drug development stage.

  — In January 2024, the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (Year 2023) (the "**NRDL**") was officially implemented. The Company has three drugs included in the new edition of the NRDL. In particular, TUOYI® has three new indications included, namely the first-line treatment of nasopharyngeal carcinoma ("**NPC**"), the first-line treatment of esophageal squamous cell carcinoma ("**ESCC**") and the first-line treatment of non-squamous non-small cell lung cancer ("**NSCLC**") and there is currently a total of six indications included in the NRDL. The indication of MINDEWEI for adult patients with mild to moderate coronavirus disease 2019 ("**COVID-19**") was officially included in the NRDL for the first time. Eight approved indications of JUNMAIKANG continued to be included in the NRDL.

  — In January 2024, Coherus BioSciences, Inc. ("**Coherus**"), a partner of the Company, announced that toripalimab was available for access and administration in the United States. Prior to that, toripalimab (U.S. trade name: LOQTORZI®) was approved for marketing by the U.S. Food and Drug Administration (the "**FDA**") in October 2023, and became the first innovative biological drug from China being included as preferred treatment options in the NPC guidelines of the National Comprehensive Cancer Network ("**NCCN**") in December 2023.

  — In January 2024, the new drug application (the "**NDA**") for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy was accepted by the Singapore Health Sciences Authority (the "**HSA**").

  — In April 2024, the Japanese Pharmaceuticals and Medical Devices Agency (the "**PMDA**") agreed that the Company may proceed with a randomized, double-blind, placebo-controlled, international multi-regional phase III clinical study of tifcemalimab (a recombinant humanized anti-BTLA monoclonal antibody, code: TAB004/JS004) in combination with toripalimab as consolidation therapy in patients with limited-stage small cell lung cancer ("**LS-SCLC**") without disease progression following chemo-radiotherapy.

- In April 2024, two supplemental new drug applications (the "**sNDA**") for ongericimab (a recombinant humanized anti-PCSK9 monoclonal antibody, code: JS002) were accepted by the National Medical Products Administration of China (the "**NMPA**").

- In April 2024, the sNDA for TUOYI® in combination with axitinib for the first-line treatment for patients with medium to high risk unresectable or metastatic renal cell carcinoma ("**RCC**") was approved by the NMPA. This is the first approved immunotherapy for renal carcinoma in China.

- In April 2024, the NDA for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy was accepted by the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region (the "**DO**").

- In June 2024, the primary endpoints of progression free survival ("**PFS**", based on independent radiographic review) and overall survival ("**OS**") of a multi-center, randomized, open-label, active controlled phase III clinical study (the "**HEPATORCH study**", NCT04723004) of TUOYI® in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma ("**HCC**") met the pre-defined efficacy boundary, and the relevant sNDA was accepted by the NMPA in July 2024.

- In June 2024, the sNDA for TUOYI® in combination with etoposidein plus platinum as the first-line treatment of extensive-stage small cell lung cancer ("**ES-SCLC**") was approved by the NMPA.

- In June 2024, the sNDA for TUOYI® in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic triple-negative breast cancer ("**TNBC**") with a well-validated test to evaluate PD-L1 positive (CPS ≥ 1) was approved by the NMPA. This is the 10th indication for toripalimab approved in Chinese mainland.

• Business operations

- As of the end of the Reporting Period, we completed the Good Manufacturing Practice ("**GMP**") and Good Clinical Practice inspections of the European Union (the "**EU**"). Currently, the European Commission (the "**EC**") is reviewing the marketing authorization applications (the "**MAA**") for toripalimab for the first-line treatment of NPC and the first-line treatment of ESCC.

- In June 2024, the Company convened the 2023 annual general meeting, the 2024 first class meeting of A shareholders and the 2024 first class meeting of H shareholders, and completed the election of the fourth session of the Board of Directors and the Board of Supervisors.

MANAGEMENT DISCUSSION AND ANALYSIS

Overview

Business Review

We have all-round capabilities in innovative drug discovery and development, clinical research on a global scale, and large-scale production capacity to commercialization on the full industry chain, with an aim to become an innovative pharmaceutical company pursuing "in China, for global". Adhering to the corporate values of being quality-oriented, realistic and pragmatic, and keeping integrity and compliance in pursuit of excellence, we are committed to develop first-in-class or best-in-class drugs by way of original innovation and co-development. With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with tremendous market potential. Multiple products have milestone significance: one of our core products, toripalimab (trade name: TUOYI® (拓益®)/LOQTORZI®, code: JS001), was the first domestic anti-PD-1 monoclonal antibody approved to be marketed in China by the NMPA, with ten indications approved and also two sNDAs accepted in Chinese mainland as of the date of this announcement, many of which are exclusive or leading indications by the Company. Moreover, toripalimab is the first innovative biological drug independently developed and manufactured in China that was approved for marketing by the FDA, and also the first and only drug approved in the United States for the treatment of NPC. In addition to the United States, the NDAs for toripalimab were accepted in various countries and regions. Our independently developed product tifcemalimab, being the world's first-in-human anti-tumor anti-BTLA monoclonal antibody, received Investigational New Drug ("**IND**") application approval from the FDA and the NMPA, and two phase III registrational clinical studies with several phase Ib/II clinical studies in combination with toripalimab against multiple types of tumors are underway.

As we continue to expand our product pipeline and further explore drug combination therapies, our innovation field has continued to expand to cover R&D of more drug modalities, including small molecules, polypeptide drugs, antibody drug conjugates (ADCs), bi-specific or multi-specific antibodies and nucleic acid drugs, as well as the exploration of the next-generation innovative therapies including cancer and autoimmune diseases. For the first half of 2024, the Company recorded revenue of RMB786 million, representing a year-on-year increase of 17%. In particular, the domestic sales revenue of our core product TUOYI® increased by approximately 50% compared with the same period last year, and the loss was significantly narrowed compared with the same period last year. Centering on our goal of "improving quality, reducing cost and enhancing efficiency", while controlling different kinds of costs, we made various major achievements in R&D, production, sales and other aspects, which are summarized as follows:

Experienced rapid growth in the revenue from sales of pharmaceutical products, and further strengthened the efficiency of commercialization and our income-generating capacity

During the Reporting Period, the Company continued to enhance the efficiency of commercialization, and experienced rapid growth in the revenue from sales of the core product toripalimab. At the same time, we continued to strengthen cost control, optimize resource allocation, and further strengthen our income-generating capacity. The domestic sales revenue of TUOYI® reached RMB671 million, representing a year-on-year increase of approximately 50%. As of the end of the Reporting Period, TUOYI® had been sold in more than 5,000 medical institutions and more than 2,000 specialty pharmacies and community pharmacies nationwide.

Starting from 2024, TUOYI® has three new indications included in the new edition of the NRDL. There are currently a total of six indications included in the NRDL. It is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma. As of the date of this announcement, TUOYI® has 10 indications approved in Chinese mainland, many of which are exclusive or leading indications by the Company.

In addition, we continuously optimized the management of the organizational structure and personnel of our commercialization team, which greatly improved the efficiency of execution and sales of our commercialization team, and made positive progress in sales. With the improved affordability and accessibility for patients by virtue of the expanded indications of toripalimab in the NDRL, the wider target population brought about by successive data readouts and approvals of more indications, as well as continuous commercialization expansion in global markets, the commercialization capabilities of toripalimab will continue to improve.

Accelerated global registration process of toripalimab, with ten indications being approved in Chinese mainland and NDAs accepted in various overseas countries

From the beginning of the Reporting Period to the date of this announcement, we continued to improve the efficiency of clinical studies and accelerate the registration process of toripalimab. It took only 36 days for a new indication from data readout to NDA acceptance by the NMPA, and various milestones were achieved in both domestic and overseas markets, further expanding the potential patient population.

During the Reporting Period, three sNDAs for TUOYI® were approved by the NMPA. As of the date of this announcement, the NMPA has approved ten indications of TUOYI®, and accepted two sNDAs, many of which are exclusive or leading indications by the Company and are expected to gain first-mover advantages in the marketing of corresponding indications:

– In April 2024, the sNDA for TUOYI® in combination with axitinib for the first-line treatment for patients with medium to high risk unresectable or metastatic RCC was approved by the NMPA. This is the first approved immunotherapy for renal carcinoma in China.

– In April 2024, the NDA for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy was accepted by the DO.

– In June 2024, the primary endpoints of PFS (based on independent radiographic review) and OS of a multi-center, randomized, open-label, active controlled phase III clinical study (the HEPATORCH study, NCT04723004) of TUOYI® in combination with bevacizumab for the first-line treatment of advanced HCC met the pre-defined efficacy boundary. In July 2024, the sNDA for TUOYI® in combination with bevacizumab for the first-line treatment of unresectable or metastatic HCC was accepted by the NMPA. It took only 36 days from data readout to NDA acceptance by the NMPA.

– In June 2024, the sNDA for TUOYI® in combination with etoposidein plus platinum as the first-line treatment of ES-SCLC was approved by the NMPA.

– In June 2024, the sNDA for TUOYI® in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic TNBC with a well-validated test to evaluate PD-L1 positive (CPS ≥ 1) was approved by the NMPA. This is the first immunotherapy approved in the field of TNBC in China, and also the 10th indication for toripalimab approved in Chinese mainland.

– In August 2024, the sNDA for TUOYI® as the first-line treatment for unresectable or metastatic melanoma has been accepted by the NMPA.

In terms of international layout, toripalimab was approved for marketing by the FDA in October 2023. In January 2024, Coherus, a partner of the Company, announced that toripalimab was available for access and administration in the United States. Toripalimab can now be ordered at all 33 NCCN institutions. We also made sound progress in the marketing applications of toripalimab in other overseas countries and regions:

– Under the pathway of Project Orbis, the New Chemical Entity (the "**NCE**") application and the NDA for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy was accepted by the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (the "**TGA**") and the HSA, respectively. Additionally, the TGA also granted an orphan drug designation and the HSA granted a priority review designation to toripalimab for the treatment of NPC. Under the framework of Project Orbis, collaboration among international regulators may allow patients with cancer to receive earlier access to new treatments in other countries. Toripalimab is the first domestic oncology drug to be included in Project Orbis. The Company will explore the possibility of expediting marketing in these countries and regions where the pathway is applicable.

– In July 2024, a positive opinion from the Committee for Medicinal Products for Human Use (the "**CHMP**") of the European Medicines Agency (the "**EMA**") was obtained for the MAA of toripalimab, which recommends approval for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic NPC, and toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC. The EC will take into account the CHMP's positive opinion when making the final decision on the MAA for toripalimab.

– The MAAs for toripalimab for the first-line treatment of NPC and the first-line treatment of ESCC were accepted by the United Kingdom's Medicines and Healthcare products Regulatory Agency (the "**MHRA**"), which are currently under review.

– The Company has been cooperating on the commercialization with partners including Hikma MENA FZE ("**Hikma**"), Dr. Reddy's Laboratories Limited ("**Dr. Reddy's**") and Rxilient Biotech Pte. Ltd. ("**Rxilient Biotech**") in over 50 countries, covering the Middle East and North Africa, Latin America, India, South Africa, Southeast Asia, Australia, and New Zealand. The Company and its partners are actively promoting the marketing application process for toripalimab within their cooperation territories, and actively exploring the possibility of marketing more indications in certain regions.

Efficiently pushed forward R&D pipelines with robust strength to sustain growth

In order to improve the efficiency of R&D, the Company integrated the laboratories in Wujiang, Suzhou and Zhangjiang, Shanghai to set up the Innovation Research Institute, which concentrated resources and operated in a unified manner to carry out the R&D of innovative drugs, accelerating the R&D work of various late-stage drug candidates so as to expand commercial presence and enhance long-term income-generating capacity.

In April 2024, the PMDA agreed that the Company may proceed with a randomized, double-blind, placebo-controlled, international multi-regional phase III clinical study (JUSTAR-001 study, NCT06095583) of tifcemalimab in combination with toripalimab as consolidation therapy in patients with LS-SCLC without disease progression following chemo-radiotherapy. As the first confirmatory study of a monoclonal antibody targeting BTLA, this study is led by academician Yu Jinming (于金明) from the Cancer Hospital affiliated to Shandong First Medical University* (山東第一醫科大學附屬腫瘤醫院) as the global principal investigator, and professor Cheng Ying (程穎) from Jilin Cancer Hospital* (吉林省腫瘤醫院) as the principal investigator in China. With the plan to be carried out in more than 190 research centers in 17 countries and regions around the world, including China, the United States, and Europe, this study will recruit about 756 subjects. As of the date of this announcement, regulatory agencies in Chinese mainland, China's Taiwan, the United States, Japan, Georgia and Turkey have approved this study to proceed. This study has completed the first patient enrollment (FPI) and the first drug administration in China, the United States, Europe and Japan, and enrollment is underway.

Based on the exceptional early data with respect to classic Hodgkin lymphoma ("**cHL**"), the Company officially initiated a randomized, open-label, active controlled, multi-center phase III clinical study (NCT06170489) of tifcemalimab in combination with toripalimab for the treatment of cHL. The study is another pivotal registrational study of tifcemalimab and also the first phase III clinical study of drugs targeting BTLA in the field of hematological tumors. It aims to evaluate the efficacy and safety of tifcemalimab in combination with toripalimab versus the chemotherapy selected by the investigator for anti-PD-(L)1 monoclonal antibody refractory cHL. Professor Song Yuqin (宋玉琴) from Peking University Cancer Hospital* (北京大學腫瘤醫院) serves as the principal investigator. It is planned for the study to be carried out in more than 50 research centers in China and approximately 185 patients will be recruited, and enrollment is underway.

Besides, several phase Ib/II clinical studies of tifcemalimab in combination with toripalimab against multiple types of tumors are underway in China and the United States. We believe that the combination of the two is a promising anti-tumor treatment strategy, which is expected to increase patients' response to immunotherapy and expand the range of potential beneficiaries.

In April 2024, two sNDAs for ongericimab were accepted by the NMPA for the treatment of: (I) heterozygous familial hypercholesterolemia; and (II) primary hypercholesterolemia and mixed dyslipidemia in which statins are not tolerated or contraindicated (monotherapy). Prior to that, the NMPA accepted the NDAs for ongericimab for the treatment of: (I) primary hypercholesterolemia and mixed dyslipidemia (combined with statins); and (II) homozygous familial hypercholesterolemia.

For our recombinant humanized anti-IL-17A monoclonal antibody (code: JS005), the Phase III registrational clinical study for moderate to severe plaque psoriasis is underway. As of the date of this announcement, all subjects have been enrolled and are being followed up.

In terms of early-stage pipelines, we will continue to focus on promoting the Claudin18.2 ADC drug (code: JS107), the oral small molecule inhibitor targeting PI3K-α (code: JS105), the CD20/CD3 bispecific antibody (code: JS203), the PD-1/VEGF bispecific antibody (code: JS207), the anti-DKK1 monoclonal antibody (code: JS015) and other products. In the course of exploration, in addition to closely tracking the clinical data of relevant indications, we will also pay attention to unmet medical needs and promote more advantageous products and indications to enter the stage of registrational clinical trials as soon as possible.

Supported business expansion by commercialization capacity

We have two commercial production bases. Both Wujiang production base in Suzhou and Shanghai Lingang production base have been granted with GMP certificates from the NMPA to commence commercial production of biological products. With a fermentation capacity of 4,500L (9*500L), Wujiang production base in Suzhou completed the Pre-License Inspection (PLI) conducted by the FDA in May 2023, and is responsible for the production of the commercial batches of toripalimab in the United States at this stage. In addition, Wujiang production base in Suzhou completed the on-site inspections conducted by the EMA, and received the CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER issued by The Ireland Health Products Regulatory Authority in accordance with the relevant regulations of the EMA in July 2024. According to the GMP mutual recognition system among the EU member states, the obtaining of the GMP certificate indicates that the production facilities with the certificate have met the GMP standards of the EU, which is an important entry condition for toripalimab's entry into the European market.

Shanghai Lingang production base has a production capacity of 42,000L (21*2,000L). The NMPA granted an approval for Shanghai Lingang production base to produce commercial batches of toripalimab injection jointly with Wujiang production base in Suzhou. By virtue of economies of scale, the expansion of production capacity of the Shanghai Lingang production base will enable us to gain the advantage of having more competitive production costs and support the clinical trials of our drug candidates and future production of commercial batches.

In order to strictly control its quality standards, the Company has established and continuously improved the quality audit mechanism which combines both internal and external audits. During the Reporting Period, the Group received external inspections/audits including the GMP on-site inspection (toripalimab injection) by the EMA, the supervision and inspection by the Jiangsu Medical Products Administration, the supervision and inspection (unannounced inspections) by the Shanghai Medical Products Administration, and audits by customers, with a scope covering MAH management system, organizational structure, production management, quality management, laboratory management, supplier management, materials and warehousing management, equipment management, drug safety, and pharmacovigilance. All entities have successfully passed the inspections/audits and are in compliance with the relevant criteria for quality management systems.

Talent development and building a compliance culture

As of the end of the Reporting Period, the Group's number of employees was 2,532, among which 652 employees are responsible for R&D of drugs. We attach importance to the attraction and development of various outstanding talents. We further improve our compensation system by establishing salary ranks and bands, taking into account competitiveness, motivation and fairness. We have also implemented an optimized performance management system across the Group, using scientific management measures to achieve the implementation of corporate strategic objectives and the continuous growth of employees' capabilities, and distinguishing between employees with high and low performance in the process, rewarding outstanding employees and disciplining the under-performing employees, thus forming a virtuous circle for the continuous output of organizational performance. In addition, we are also gradually improving promotion channels and policies within the enterprise to open up career development paths for high-performing and high-potential employees. At the same time, we also care about the working environment of our employees and continue to provide them with numerous employee benefits, including holiday care and a variety of employee activities throughout the year to enrich their work experience. We believe that our comprehensive and excellent talent team can provide inexhaustible impetus to support the Company in continuously advancing numerous innovative drugs from R&D to commercialization.

Keeping integrity and compliance is the fundamental rule of our operations. Upholding a corporate culture of operation compliance as always, we are committed to building a compliance system at a high standard, strictly complying with relevant national laws and regulations and the regulatory policies of the pharmaceutical industry, and providing patient-centered treatment options which have better efficacy and greater cost-effectiveness. We encourage our employees to comply with laws and regulations related to the products or services of the Company as well as the highest standards of business and personal ethics. Against the backdrop of stringent regulation in the pharmaceutical industry, we will continue to build a compliance culture of "innovation-driven, academic promotion" and optimize our compliance system of "full-process guidance and supervision" to enhance the quality and efficiency of our operations and management, and to facilitate high-quality and sustainable development.

Product Pipelines

Our products concentrate on self-developed biological products with original innovation. At the same time, through co-development, formation of joint ventures, license-in and other means, we obtained the licenses of drugs or platform technologies that synergized with our own original product pipeline, so as to further expand our product pipeline. After prolonged accumulation of drug development technology, in-depth exploration in the field of translational medicine and the establishment of a new drug type platform, our innovative R&D field has expanded from monoclonal antibodies to the research and development of more drug modalities, including small molecule drugs, polypeptide drugs, antibody drug conjugates (ADCs), bi-specific or multi-specific antibodies and nucleic acid drugs, as well as the exploration of next-generation innovative therapies for cancer and autoimmune diseases. The Company's product pipelines cover five major therapeutic areas including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. As of the date of this announcement, a total of three drugs (TUOYI®, JUNMAIKANG and MINDEWEI) are being commercialized, around 30 drug candidates are undergoing clinical trials, and over 20 drug candidates are at preclinical drug development stage.

Projects Entering the Clinical R&D Stage (As of 30 August 2024)



Note 1: Received Emergency Use Authorization (EUA) from the FDA
Note 2: The products listed herein are products that have obtained IND approvals as announced

R&D Progress of Toripalimab

Therapeut Area	Medicine Code	Clinical Trial Number	Indications	Pre-Clinical	Phase I	Phase	Phase III	NDA
Oncology	JS001 Toripalimab	NCT03013101	Melanoma (second-line treatment, monotherapy)	NMPA approved on 17 December 2018				
		NCT02915432	Nasopharyngeal carcinoma (second-line and later treatment, monotherapy)	NMPA approved (third -line) in February 2021, FDA approved in October 2023, marketing application accepted by multiple locations				
		NCT03113266	Urothelial carcinoma (second-line treatment, monotherapy)	NMPA approved in April 2021				
		NCT03581786	Nasopharyngeal carcinoma (first-line treatment, combo with chemo)	NMPA approved in November 2021, FDA approved in October 2023, marketing application accepted by multiple locations				
		NCT03829969	Esophageal squamous cell carcinoma (first-line treatment, combo with chemo)	NMPA approved in May 2022, marketing application accepted by EMA and MHRA				
		NCT03856411	EGFR-negative non-small cell lung cancer (first-line treatment, combo with chemo)	NMPA approved in September 2022				
		NCT04158440	Non-small cell lung cancer (perioperative treatment)	NMPA approved in December 2023				
		NCT04394975	Renal cell carcinoma (first-line treatment, combo with axitinib)	NMPA approved in April 2024				
		NCT04012606	Small cell lung cancer (first-line treatment, combo with chemo)	NMPA approved in June 2024				
		NCT04085276	Triple-negative breast cancer (combo with albumin-bound paclitaxel)	NMPA approved in June 2024				
		NCT04723004	Hepatocellular carcinoma (first-line treatment, combo with bevacizumab)	sNDA accepted by the NMPA				
		NCT03430297	Melanoma (first-line treatment, monotherapy)	sNDA accepted by the NMPA				
		NCT03924050	EGFR-mutated TKI-failed terminal stage non-small cell lung cancer (combo with chemo)	Pivotal registered clinical trial				
		NCT04848753	Esophageal squamous cell carcinoma (perioperative treatment)	Pivotal registered clinical trial				
		NCT04523493	Hepatocellular carcinoma (first-line treatment, combo with lenvatinib)	Pivotal registered clinical trial				
		NCT03859128	Hepatocellular carcinoma (postoperative adjuvant treatment)	Pivotal registered clinical trial				
		NCT05342194	Intrahepatic cholangiocarcinoma (first-line treatment, combo with lenvatinib and chemo)	Pivotal registered clinical trial				
		NCT05302284	Urothelial carcinoma (first-line treatment, combo with disitamab vedotin)	Pivotal registered clinical trial				
		NCT05180734	Adenocarcinoma of the stomach or gastroesophageal junction (postoperative adjuvant treatment)	Pivotal registered clinical trial				

Our Core Products

TUOYI® (toripalimab, code: TAB001/JS001)

- *Milestones and achievements of commercialization*

  During the Reporting Period, TUOYI® recorded domestic sales revenue of approximately RMB671 million, representing a year-on-year increase of approximately 50%. Our self-developed toripalimab is the first domestic anti-PD-1 monoclonal antibody successfully launched in China, and is also the first innovative biological drug independently developed and manufactured in China that was approved for marketing by the FDA, addressing various malignant tumors. It was granted the "China Patent Gold Award", the highest award in the patent field nationally, and has been supported by two National Major Science and Technology Projects for "Major New Drugs Development" during the "Twelfth Five-Year Plan" and "Thirteenth Five-Year Plan" periods. The Company continued to make positive progress in sales with the increased number of toripalimab's approved indications and NRDL-included indications, improved execution of its commercialization team and international expansion.

  As of the date of this announcement, toripalimab has ten indications approved in Chinese mainland:

  - treatment for unresectable or metastatic melanoma after failure of standard systemic therapy (December 2018);
  - treatment for recurrent/metastatic NPC after failure of at least two lines of prior systemic therapy (February 2021);
  - treatment for locally advanced or metastatic urothelial carcinoma ("**UC**") that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy (April 2021);
  - first-line treatment in combination with cisplatin and gemcitabine for patients with locally recurrent or metastatic NPC (November 2021);
  - first-line treatment in combination with paclitaxel and cisplatin for patients with unresectable locally advanced/recurrent or distant metastatic ESCC (May 2022);
  - first-line treatment in combination with pemetrexed and platinum for patients with EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous NSCLC (September 2022);
  - treatment in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB NSCLC (December 2023);
  - first-line treatment in combination with axitinib for patients with medium to high risk unresectable or metastatic RCC (April 2024);

- first-line treatment in combination with etoposidein plus platinum for ES-SCLC (June 2024);

- first-line treatment in combination with paclitaxel for injection (albumin-bound) for recurrent or metastatic TNBC with a well-validated test to evaluate PD-L1 positive (CPS ≥ 1) (June 2024).

Two sNDAs of TUOYI® have also been accepted by the NMPA. In April 2024, the NDA for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy was accepted by the DO. In addition, TUOYI® has been recommended by the Guidelines of Chinese Society of Clinical Oncology ("**CSCO**") for the Diagnosis and Treatment of NPC* (《CSCO 鼻咽癌診療指南》), for the Diagnosis and Treatment of Head and Neck Tumors* (《CSCO 頭頸部腫瘤診療指南》), for the Diagnosis and Treatment of NSCLC* (《CSCO 非小細胞肺癌診療指南》), for the Diagnosis and Treatment of SCLC* (《CSCO 小細胞肺癌診療指南》), for the Diagnosis and Treatment of Breast Cancer* (《CSCO 乳腺癌診療指南》), for the Diagnosis and Treatment of Esophageal Cancer* (《CSCO 食管癌診療指南》), for the Diagnosis and Treatment of Renal Cancer* (《CSCO 腎癌診療指南》), for Immune Checkpoint Inhibitor Clinical Practice* (《CSCO 免疫檢查點抑制劑臨床應用指南》) and others.

Starting from January 2024, TUOYI® has three new indications included in the new edition of the NRDL. There are currently a total of six indications included in the NRDL. It is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma. The inclusion of new indications of TUOYI® in the NRDL will further expand the coverage of patients with various types of cancers who may gain benefits, reduce the medical burden for patients and their families, and improve the affordability and accessibility of TUOYI® among patients.

In recent years, we continuously optimized the management of the organizational structure of our commercialization team, which greatly improved the efficiency of execution and sales of our commercialization team. As of the end of the Reporting Period, TUOYI® had been sold in more than 5,000 medical institutions and more than 2,000 specialty pharmacies and community pharmacies nationwide.

In terms of international layout, toripalimab had been approved for marketing as the first nasopharyngeal cancer drug in the United States in October 2023, and has been officially marketed in the United States from January 2024. In July 2024, a positive opinion from the CHMP of the EMA was obtained for the MAA of toripalimab, which recommends approval for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic NPC, and toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC. The EC will take into account the CHMP's positive opinion when making the final decision on the MAA for toripalimab. In addition, the MHRA accepted the MAA for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC, and toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC. The TGA and the HSA accepted the NCE application

and the NDA for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy, respectively.

- *Milestones and achievements of clinical development*

Over 40 clinical studies covering more than 15 indications in respect of toripalimab have been conducted in China, the United States, Southeast Asia, Europe and other regions, involving indications such as lung cancer, nasopharyngeal cancer, esophageal cancer, gastric cancer, bladder cancer, breast cancer, liver cancer, renal cancer and skin cancer. Among the pivotal registered clinical studies, the Company has actively deployed perioperative treatment/postoperative adjuvant treatment for various types of tumors in addition to the extensive layout of toripalimab for the first-line treatment of multiple tumor types, to promote the application of cancer immunotherapy in the early treatment of cancer patients.

Progress of clinical trials in China:

– In April 2024, the sNDA for TUOYI® in combination with axitinib for the first-line treatment for patients with medium to high risk unresectable or metastatic RCC was approved by the NMPA. This is the first approved immunotherapy for renal carcinoma in China.

– In April 2024, the NDA for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy was accepted by the DO.

– In June 2024, the primary endpoints of PFS (based on independent radiographic review) and OS of a multi-center, randomized, open-label, active controlled phase III clinical study (the HEPATORCH study, NCT04723004) of TUOYI® in combination with bevacizumab for the first-line treatment of advanced HCC met the pre-defined efficacy boundary. In July 2024, the sNDA for TUOYI® in combination with bevacizumab for the first-line treatment of unresectable or metastatic HCC was accepted by the NMPA.

– In June 2024, the sNDA for TUOYI® in combination with etoposidein plus platinum as the first-line treatment of ES-SCLC was approved by the NMPA.

– In June 2024, the sNDA for TUOYI® in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic TNBC with a well-validated test to evaluate PD-L1 positive (CPS ≥ 1) was approved by the NMPA. This is the 10th indication for toripalimab approved in Chinese mainland.

– In August 2024, the sNDA for TUOYI® as the first-line treatment for unresectable or metastatic melanoma has been accepted by the NMPA.

Pivotal Registration Clinical Trial Layout of Toripalimab



International progress:

– In January 2024, the NDA for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy was accepted by the HSA, which was granted a priority review designation by the HSA.

– In July 2024, a positive opinion from the CHMP was obtained for the MAA of toripalimab, which recommends approval for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic NPC, and toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC. The EC will take into account the CHMP's positive opinion when making the final decision on the MAA for toripalimab.

- *Publication of academic results*

From the beginning of the Reporting Period to the date of this announcement, the milestones achieved in clinical studies of toripalimab have also been included in presentations of many international academic conferences and journals, details of which are as follows:

— In January 2024, the results of the phase III clinical study (TORCHLIGHT study) of toripalimab in combination with paclitaxel (albumin-bound) (nab-P) for the treatment for patients with initial diagnosis of stage IV or recurrent metastatic TNBC were published in *Nature Medicine* (IF: 58.7), a leading international medical journal. This is another international academic recognition of the TORCHLIGHT study following its oral presentation in the fast abstract session at the 2023 American Society of Clinical Oncology ("**ASCO**") annual meeting in the form of a late-breaking abstracts (LBA). According to the study, toripalimab in combination with nab-P can significantly improve PFS, providing a promising new treatment strategy for patients with PD-L1-positive initial diagnosis of stage IV or recurrent metastatic TNBC.

— In January 2024, the final results of a prospective, randomized, open-label phase II clinical study (NEOSUMMIT-01) for locally advanced gastric or gastro-esophageal junction cancer (GC/GEJC) were published online in *Nature Medicine* (IF: 58.7). The study is the first reported randomized controlled clinical study in the world that achieved the primary endpoint of perioperative immunotherapy combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer, provides an effective treatment option for locally advanced gastric cancer, and was successfully selected for an oral presentation at the 2023 ASCO annual meeting.

— In January 2024, the phase III clinical study (NEOTORCH study) of toripalimab in combination with chemotherapy for the perioperative treatment of resectable NSCLC was published in *Journal of the American Medical Association* (*JAMA*, IF: 63.1), a leading international authoritative journal, and became the world's first study for the perioperative immunotherapy of lung cancer (covering neoadjuvant and adjuvant therapy) featured in *JAMA*. Prior to that, the results of the event-free survival ("**EFS**") interim analysis of the NEOTORCH study were announced at the April session of the 2023 ASCO Plenary Series and the ASCO annual meeting.

— In January 2024, the full text of the SCALE-1 study (ChiCTR2100045104) of short-course chemoradiotherapy combined with toripalimab for the neoadjuvant therapy of locally advanced ESCC was published in *Journal for ImmunoTherapy of Cancer* (*JITC*, IF: 10.3), an authoritative journal for tumor immunotherapy. It is the first clinical study of short-course neoadjuvant chemoradiotherapy combined with immunotherapy for esophageal cancer domestically and overseas, which provides a neoadjuvant therapy option for patients with resectable locally advanced esophageal cancer with significant benefits and greater safety.

- In January 2024, a single-arm phase II clinical study of toripalimab in combination with capecitabine for the treatment for patients with residual NPC was published in *Nature Communication* (IF: 14.7), a journal under the internationally renowned authoritative journal *Nature*. As the first clinical study with the largest sample size on the treatment of residual NPC, the study indicated that toripalimab in combination with capecitabine exhibited favourable and durable anti-tumor activity in patients with residual NPC after definitive treatment. The ORR was 95.7%, of which 56.6% of patients achieved complete response (CR), and the 1-year and 2-year PFS rates were 95.7% and 82.4%, respectively. The regimen demonstrated a good safety profile, and no grades 4-5 treatment-related adverse events (TRAE) was recorded.

- In January 2024, the results of the first Phase II clinical study (INSIGHT study) evaluating immunotherapy combined with induction chemotherapy for laryngeal preservation treatment in patients with locally advanced laryngeal cancer and hypopharyngeal cancer were published in *Clinical Cancer Research* (IF: 10.0), an internationally renowned oncology journal. For patients with locally advanced laryngeal cancer and hypopharyngeal cancer, the combination therapy with toripalimab demonstrated significant laryngeal preservation effects and long-term survival benefits, providing an effective, safe and tolerable potential laryngeal preservation option for patients.

- In February 2024, the results of a phase II clinical study of toripalimab in combination with axitinib for neoadjuvant therapy in patients with resectable mucosal melanoma were published in *Annals of Oncology* (IF: 56.7), an international authoritative medical journal as well as the official journal of the European Society for Medical Oncology (ESMO), and became the latest results of the first neoadjuvant therapy for mucosal melanoma presented by China to the world. The study results showed that toripalimab in combination with axitinib for neoadjuvant therapy in patients with resectable mucosal melanoma reported a pathologic response rate of 33.3% and a median recurrence-free survival (RFS) of 11.7 months in responders.

- In March 2024, the results of the exploratory analysis of a prospective phase II study of toripalimab combined with definitive chemoradiotherapy for the treatment of locally advanced esophageal cancer – the predictive role of circulating tumor DNA (ctDNA) and blood-based tumor mutational burden (bTMB) were published in *Nature Communication* (IF: 14.7). Prior to that, the major results of the study were published in *The Lancet Oncology* (IF: 41.6), a leading international oncology journal, providing strong evidence for the application of immunotherapy in locally advanced esophageal cancer, and expecting to provide a new treatment option for patients.

- In March 2024, a study of neoadjuvant chemoradiotherapy (nCRT) combined with sequential perioperative toripalimab for the treatment of locally advanced ESCC was published in *Journal For Immunotherapy Of Cancer* (*JITC*, IF: 10.3). The study is the first prospective clinical study to evaluate the feasibility of neoadjuvant chemoradiotherapy combined with sequential anti-PD-1 monoclonal antibody toripalimab in resectable ESCC. The results showed that nCRT combined with sequential perioperative toripalimab for the treatment of locally advanced ESCC exhibited an encouraging efficacy, with a MPR rate of 78.9% and a pCR rate of 47.4%, while maintaining a good safety profile, demonstrating the feasibility of nCRT combined with sequential toripalimab for the treatment of resectable ESCC, and it is a highly potential treatment option.

- In April 2024, the results of the five-year long-term follow-up of the POLARIS-01 study to investigate the safety and efficacy of toripalimab for the treatment advanced melanoma were published in *The Oncologist* (IF: 4.8), an international medical journal. The POLARIS-01 study is the largest prospective study of anti-PD-1 treatment in advanced melanoma with mature data in China, and its major analysis and study results were previously published in the magazine *Clinical Cancer Research* (IF: 10.0). This update of the five-year follow-up results of the POLARIS-01 study showed that toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma who had failed in standard therapy, with a median duration of response (DoR) of 15.6 months, a median OS of 20 months, and a 60-month OS rate of 28.5%. No new safety signal was detected.

- In June 2024, the results of the phase II clinical study of toripalimab in combination with bevacizumab for advanced HCC were published in *Clinical Cancer Research* (IF: 10.0). The study results showed that toripalimab in combination with bevacizumab for the first-line treatment of advanced HCC exhibited encouraging efficacy and survival benefit. As assessed by the investigator according to RECIST v1.1, the ORR was 31.5%, and the median PFS was 8.5 months. The IRC assessed ORR according to mRECIST criteria, which was 46.3%, and the median PFS was 9.8 months, and the safety profile was good. The combination can be used as a potential new treatment option for the first-line treatment for patients with advanced HCC. Prior to that, the preliminary results of the study were presented at the 2022 ASCO GI Symposium.

- In June 2024, a phase II clinical study of toripalimab in combination with axitinib for the neoadjuvant therapy of locally advanced clear cell RCC was published in *Journal For Immunotherapy Of Cancer* (*JITC*, IF: 10.3*)*. Prior to that, the study results were presented at the 2024 American Urological Association (AUA) annual meeting (Abstract No.: PD33-07). The study indicated the efficacy of toripalimab in combination with axitinib as a neoadjuvant therapy, particularly in patients with a high burden of tumor thrombus, exhibiting significant anti-tumor activity and improved prognosis, and providing new evidence for perioperative immunotherapy combined with targeted therapy in locally advanced RCC.

- In June 2024, a total of more than 30 studies on toripalimab were selected at the 2024 ASCO annual meeting, covering various fields such as head and neck cancer, lung cancer, gastric/esophageal cancer, liver cancer, colorectal cancer, bladder cancer and melanoma. Being applied in a variety of combination therapies, toripalimab as a cornerstone drug in the immuno-oncology (I-O) field demonstrated its importance and potential for having a diversified product portfolio.

Tifcemalimab (code: TAB004/JS004)

Tifcemalimab is the world's first-in-human recombinant humanized anti-tumor anti-BTLA monoclonal antibody specific to B-and T-lymphocyte attenuator (BTLA) independently developed by us that has commenced clinical trial. BTLA is expressed in the T lymphocyte, B lymphocyte, and dendritic cell subpopulations. In 2005, the interaction between BTLA and its ligand, Herpes virus entry mediator (HVEM), was discovered. HVEM, a TNF receptor, is extensively expressed in the hematopoietic system and has been confirmed as the ligand of BTLA. By binding with BTLA, tifcemalimab blocks the HVEM-BTLA interaction, thereby obstructing the BTLA-mediated inhibitory signal pathways and activating the tumor-specific lymphocytes.

Tifcemalimab entered phase III clinical stage, with several phase Ib/II clinical studies in combination with toripalimab against multiple types of tumors underway in China and the United States. We believe that the combination of the two is a promising anti-tumor treatment strategy, which is expected to increase patients' response to immunotherapy and expand the range of potential beneficiaries.

- *Milestones and achievements of clinical development*

  Our two Phase III registrational clinical studies for tifcemalimab are underway:

  – The JUSTAR-001 study is a randomized, double-blind, placebo-controlled, international multi-regional phase III clinical study, and is aimed to evaluate the efficacy and safety of tifcemalimab in combination with toripalimab compared to toripalimab alone and compared to placebo as consolidation therapy used in LS-SCLC patients without disease progression following chemoradiotherapy. As the first confirmatory study of a monoclonal antibody targeting BTLA, this study is led by academician Yu Jinming (于金明) from the Cancer Hospital affiliated to Shandong First Medical University* (山東第一醫科大學附屬腫瘤醫院) as the global principal investigator, and professor Cheng Ying (程穎) from Jilin Cancer Hospital* (吉林省腫瘤醫院) as the principal investigator in China. With the plan to be carried out in more than 190 research centers in 17 countries and regions around the world, including China, the United States, and Europe, this study will recruit about 756 subjects. As of the date of this announcement, regulatory agencies in Chinese mainland, China's Taiwan, the United States, Japan, Georgia and Turkey have approved this study to proceed. This study has completed the first patient enrollment (FPI) and the first drug administration in China, the United States, Europe and Japan, and enrollment is underway;

  – The JS004-009-III-cHL study (NCT06170489) is a randomized, open-label, active controlled, multi-center phase III clinical study, and aims to evaluate the efficacy and safety of tifcemalimab in combination with toripalimab versus the chemotherapy selected by the investigator for anti-PD-(L)1 monoclonal antibody refractory cHL. This study is the first phase III clinical study of drugs targeting BTLA in the field of hematological tumors. Professor Song Yuqin (宋玉琴) from Peking University Cancer Hospital* (北京大學腫瘤醫院) serves as the principal investigator. It is planned for the study to be carried out in more than 50 research centers in China and approximately 185 patients will be recruited, and enrollment is underway.

  In addition, several phase Ib/II clinical studies of tifcemalimab in combination with toripalimab against multiple types of tumors are underway in China and the United States. Upon further data collection, we will make plans for subsequent registrational clinical studies based on our clinical data and communication with regulators to promote the application and commercialization of tifcemalimab in combination with toripalimab in more tumor types.

- *Publication of academic results*

  The preliminary clinical study results of tifcemalimab alone or in combination with toripalimab have been presented at various international medical conferences. The combination demonstrated good safety profiles and encouraging efficacy in patients with small cell lung cancer, relapsed/refractory (R/R) lymphoma, and immune-refractory advanced solid tumors who have failed multiple lines of therapy.

  – At the 2024 ASCO annual meeting, we displayed a poster (Abstract No.: #8089) containing the preliminary results of the phase I/II clinical study of tifcemalimab in combination with toripalimab and chemotherapy as the first-line treatment of ES-SCLC for the first time. The study is a multi-cohort, open-label, multi-center phase Ib/II clinical study (NCT05664971) led by Professor Lu Shun from the Shanghai Chest Hospital, and is designed to evaluate the safety and efficacy of tifcemalimab in combination with toripalimab and chemotherapy as the first-line treatment for patients with advanced lung cancer. Preliminary data showed that ES-SCLC patients without previous systemic anti-tumor therapy received tifcemalimab (200mg, Q3W) in combination with toripalimab (240mg, Q3W) and standard chemotherapy (etoposide + carboplatin/cisplatin) for 4 cycles, then followed by tifcemalimab plus toripalimab maintenance therapy, showing good anti-tumor effect: 1) Among 43 evaluable patients, the ORR of tifcemalimab in combination with toripalimab and chemotherapy as first-line treatment was 86.0%, the disease control rate ("**DCR**") was 100%, and the median DoR was 4.3 months. PFS was 5.4 months, and the median OS was not reached; 2) Manageable safety profile: 97.7% of patients experienced treatment-emergent adverse events (TEAEs), and 88.6% of patients experienced ≥ grade 3 TEAEs. 29.5% of patients experienced immune-related adverse events (irAEs). Tifcemalimab in combination with toripalimab and chemotherapy as the first-line treatment of ES-SCLC showed encouraging clinical response rates with a manageable safety profile. The study will further evaluate patient survival benefit and long-term safety.

  – At the 2024 ASCO annual meeting, we announced the results of the phase I dose-escalation and cohort-expansion study of tifcemalimab in combination with toripalimab for American patients with advanced malignancies (Abstract No.: #2596). A total of 16 patients with advanced malignancies who had failed prior standard therapies were enrolled in the dose-escalation phase, and were administered with tifcemalimab (20mg, 70mg, 200mg and 500mg, Q3W) in combination with toripalimab (240mg, Q3W). A total of 75 patients were enrolled in the cohort-expansion phase, in which five cohorts (i.e. lymphoma, melanoma, RCC, NSCLC and UC) were selected for the treatment with tifcemalimab (200mg, Q3W) in combination with toripalimab (240mg, Q3W). All patients were pretreated with a median of 4 prior lines of therapy, and 75.8% of them had received anti-PD-(L)1 monoclonal antibody treatment. Results showed that: for the melanoma cohort (18 patients with evaluable efficacy), ORR was 17%, and DCR was 39%; for the RCC cohort (11 patients with evaluable efficacy), ORR was 18%, and DCR was 73%; for the NSCLC cohort (17 patients with evaluable efficacy), ORR was 6%, and DCR was 42%; for the UC cohort (9 patients with evaluable efficacy), ORR was 11%, and DCR was 22%. Results showed that tifcemalimab in combination with toripalimab showed preliminary efficacy with a manageable safety profile in patients with relapsed/refractory tumors who had failed multiple lines of immunotherapy (IO) treatment. Prior to that, the preliminary results of the study on tifcemalimab monotherapy for advanced solid tumors were presented at the 2022 ASCO meeting, showing the good anti-tumor activity and safety of tifcemalimab.

R&D Progress of Tifcemalimab

Therapeutic Area	Target	Indications	Mono or Combo	Pre-Clinical	Phase I	Phase II	Phase III	Locations of Clinical Trial
Oncology	BTLA tifcemalimab	Lung cancer: Limited stage small cell lung cancer	tifcemalimab+toripalimab					International multi-regional
		Lung cancer: Extensive-stage small cell lung cancer (first line)	tifcemalimab+toripalimab+chemo					China
		Lung cancer: Refractory extensive-stage small cell lung cancer	tifcemalimab+toripalimab					China
		Lung cancer: Advanced non-small cell lung cancer (first line)	tifcemalimab+toripalimab±chemo					China
		Lung cancer: Advanced non-small cell lung cancer (≥ second line)	tifcemalimab+toripalimab					China
		Lung cancer: Advanced non-small cell lung cancer (neoadjuvant)	tifcemalimab+toripalimab					China
		Classic Hodgkin lymphoma	tifcemalimab+toripalimab					China
		Advanced head and neck cancer	tifcemalimab±toripalimab					China
		Melanoma	tifcemalimab±toripalimab					China
		Renal cell carcinoma	tifcemalimab±toripalimab					China
		Urothelial carcinoma	tifcemalimab±toripalimab					China
		Advanced malignancies (solid tumors and lymphomas)	tifcemalimab±toripalimab					United States
		Advanced solid tumors	tifcemalimab+toripalimab					China
		Malignant lymphoma	tifcemalimab±toripalimab					China

Other Key Products

MINDEWEI (Deuremidevir Hydrobromide Tablets, code: JT001/VV116)

MINDEWEI is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase ("**RdRp**") of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect. Preclinical studies have shown that MINDEWEI exhibited significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, and exhibited no genetic toxicity. MINDEWEI was jointly developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences* (中國科學院上海藥物研究所), Wuhan Institute of Virology, Chinese Academy of Sciences* (中國科學院武漢病毒研究所), Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences* (中國科學院新疆理化技術研究所), Central Asian Center of Drug Discovery and Development of Chinese Academy of Sciences* (中國科學院中亞藥物研發中心)/China-Uzbekistan Medicine Technical Park (the Belt and Road Joint Laboratory of the Ministry of Science and Technology)* (中烏醫藥科技城(科技部"一帶一路"聯合實驗室)), Lingang Laboratory* (臨港實驗室), Suzhou Vigonvita Biomedical Co., Ltd.* (蘇州旺山旺水生物醫藥有限公司) and the Company.

On 28 January 2023, the marketing of MINDEWEI for the treatment of adult patients with mild to moderate COVID-19 was conditionally approved by the NMPA. MINDEWEI was included in the scope of provisional medical insurance reimbursement in January 2023, and has been officially included in the NRDL since January 2024.

After MINDEWEI was being marketed, the Company actively established a commercialization team, continuously explored sales models, and included a new sales promotion model and an internal team for MINDEWEI based on the coverage of its existing internal hospital sales team for TUOYI®. All members of the new sales team have extensive experience in promotion in the field of respiratory infections. We will continue to expand the coverage of MINDEWEI in hospitals and further improve the accessibility of MINDEWEI. As of the end of the Reporting Period, MINDEWEI had been used in more than 2,300 hospitals, including community healthcare service centers, secondary hospitals and tertiary hospitals, covering all provinces in the territory.

JUNMAIKANG (君邁康®) (adalimumab, code: UBP1211)

JUNMAIKANG is an adalimumab jointly developed by us, Mabwell (Shanghai) Bioscience Co., Ltd.* (邁威(上海)生物科技股份有限公司) and its subsidiaries. As our third commercialized product, JUNMAIKANG has received support from the national "Major New Drug Development", a major scientific and technological project, during the "Twelfth Five-Year Plan", which would bring new treatment options for Chinese patients at large with autoimmune disease after its launch. In March 2022, the marketing of JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis was approved by the NMPA, with the first prescription issued in May 2022. In November 2022, the supplemental application for five additional indications of JUNMAIKANG for the treatment of Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn's disease was approved by the NMPA. Under the continuous promotion of our commercialization partners, JUNMAIKANG was newly used in 55 hospitals during the Reporting Period. As of the end of the Reporting Period, JUNMAIKANG completed the tendering process on the procurement platform as well as healthcare and insurance connection in 26 provinces, and has been used in 243 hospitals, covering 1,303 pharmacies.

Ongericimab (code: JS002)

Ongericimab is a recombinant humanized anti-PCSK9 monoclonal antibody independently developed by us. The Company completed two Phase III clinical studies in patients with primary hypercholesterolemia (including familial and non-familial heterozygous) and mixed hyperlipidemia, a Phase II clinical study in patients with homozygous familial hypercholesterolemia, and a Phase III clinical study in patients with heterozygous hypercholesterolemia. In addition, a Phase III clinical study of monotherapy in patients with primary hypercholesterolemia and mixed hyperlipidemia (statin intolerance and intermediate to low cardiovascular risk) finished the primary analysis.

In April 2024, two sNDAs for ongericimab were accepted by the NMPA for the treatment of: (I) heterozygous familial hypercholesterolemia (monotherapy); and (II) primary hypercholesterolemia and mixed dyslipidemia in which statins are not tolerated or contraindicated. Prior to that, the NMPA accepted the NDAs for ongericimab for the treatment of: (I) primary hypercholesterolemia and mixed dyslipidemia (combined with statins); and (II) homozygous familial hypercholesterolemia.

In May 2024, the results of the Phase III clinical study of ongericimab for the treatment of primary hypercholesterolemia and mixed hyperlipidemia (study no.: JS002-006) were published in *Nutrition Metabolism And Cardiovascular Diseases*, an international academic journal for endocrinology and metabolism. In June 2024, the results of the Phase III clinical study of ongericimab for the treatment of primary hypercholesterolemia and mixed dyslipidemia (study no.: JS002-003) were published in *Journal of the American Heart Association*.

Recombinant humanized anti-IL-17A monoclonal antibody (code: JS005)

JS005 is a specific anti-IL-17A monoclonal antibody developed independently by us. In preclinical studies, JS005 has shown efficacy and safety comparable to those of anti-IL-17 monoclonal antibodies that have been marketed. Data from preclinical study fully depicts that JS005 has a clear target, definite efficacy, good safety, stable production process, and controllable product quality. At the 2023 annual meeting of the American College of Rheumatology (ACR), we announced the results of the Phase Ib/II clinical study of JS005 for the treatment for patients with moderate to severe psoriasis for the first time. The study results showed that JS005 has a good safety profile in the treatment for patients with moderate to severe plaque psoriasis. Compared with placebo, JS005 significantly improved the Psoriasis Area and Severity Index of patients ($p<0.0001$). The Phase III registrational clinical study of JS005 for moderate to severe plaque psoriasis is underway. As of the date of this announcement, all subjects have been enrolled and are being followed up.

Recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207)

JS207 is a recombinant humanized anti-PD-1/VEGF bispecific antibody self-developed by the Company, mainly used for the treatment of advanced malignant tumors. In view of the co-expression of VEGF and PD-1 in the tumor microenvironment, JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, block the binding of PD-1 to PD-L1 and PD-L2 while blocking the binding of VEGF to the VEGF receptor. JS207 has the efficacy properties of both immunotherapeutic drugs and anti-angiogenic drugs, and can utilize the synergistic effects of immunotherapy and anti-angiogenesis to achieve better anti-tumor activity. The combination therapy with PD-1 antibody and VEGF blocking agent has shown strong efficacy in a variety of tumor types such as RCC, NSCLC and HCC. Compared with combination therapy, JS207 as a single agent blocking both targets, may be more effective in blocking both pathways and thus enhancing anti-tumor activity. Preclinical in vivo efficacy trials have demonstrated that JS207 has a significant anti-tumor effect, presenting a dose effect as well. In addition, JS207 is well tolerated by animals. As of the date of this announcement, the phase I clinical study for JS207 is underway.

Recombinant humanized anti-CD20/CD3 bispecific antibody (code: JS203)

JS203 is a recombinant humanized anti-CD20/CD3 bispecific antibody self-developed by the Company. CD20 is a B lymphocyte restricted differentiation antigen and one of the most successful targets for B-cell lymphoma treatment. CD3 is an important marker on the surface of T cell. The main mechanism of T cell engaging bispecific antibodies is using CD3 as a mediator to activate T cells to specifically attack tumor cells. JS203 consists of anti-CD20 segment and anti-CD3 segment. By associating and activating T cells (binding to CD3) and lymphoma cells (binding to CD20), JS203 can enable T cells to kill lymphoma cells effectively. Pre-clinical in vivo pharmacodynamics shows that JS203 has a significant anti-tumor effect. In addition, JS203 is well tolerated by animals. As of the date of this announcement, the phase I clinical study for JS203 is underway.

PI3K-α inhibitor (code: JS105)

JS105 is an oral small molecule inhibitor targeting PI3K-α jointly developed by the Company and Risen (Suzhou) Pharma Tech Co., Ltd.* (潤佳(蘇州)醫藥科技有限公司), and is primarily used in the treatment of female (postmenopausal) and male patients with hormone receptor (HR)-positive, human EGFR 2 (HER-2)-negative, PIK3CA-mutated, advanced breast cancer who are experiencing disease progression during or after treatment with endocrine-based regimens. Preclinical studies have shown that JS105 is effective in animal models of breast cancer, and has better efficacy for patients with other solid tumors such as cervical cancer, renal cancer, colorectal cancer and esophageal cancer. JS105 has also demonstrated good safety. As of the date of this announcement, the phase I/II clinical studies on the JS105's monotherapy and combination treatment are underway.

Recombinant humanized anti-Claudin18.2 monoclonal antibody-MMAE conjugate (code: JS107)

JS107 is a recombinant humanized anti-Claudin18.2 monoclonal antibody-MMAE (Monomethyl auristatin-E) conjugate for injection developed independently by the Company. It is an antibody-drug conjugate (ADCs) targeting tumor-related protein Claudin18.2, and is intended to be used for the treatment of advanced malignant tumors, such as gastric cancer and pancreatic cancer. JS107 can bind to Claudin18.2 on the surface of tumor cells, enter into tumor cells through endocytosis, and release the small molecule toxin MMAE, which has demonstrated strong lethality to tumor cells. JS107 also retained antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) effects, further killing tumor cells. Furthermore, due to the cell permeability of MMAE, JS107 can mediate indiscriminate killing of other tumor cells by way of its bystander effect, thereby improving the efficacy of treatment and inhibiting tumor recurrence. The preclinical in vivo pharmacodynamics showed that JS107 exhibits significant anti-tumor effect. As of the date of this announcement, the phase I/II clinical studies on the JS107's monotherapy and combination treatment are underway.

Future and Prospects

With strong R&D capabilities, we are at the forefront of medical innovation. In respect of R&D of drugs, we will accelerate late-stage pipeline R&D and marketing application. We will also continue to explore early-stage pipelines and closely track relevant clinical trial data, aiming to facilitate the progress of clinical trial registration for more advantageous products and indications, thus creating a sustainable impetus for the future revenue growth of the Company. Meanwhile, we will also invest appropriate resources to explore and develop new drug targets and drug types. Based on independent R&D, we will further enhance cooperation and expand the product pipeline through license-in, formation of joint ventures and other methods to stay on the front line of R&D of innovative drugs. As for production, we plan to further increase the fermentation capacity of macromolecular drugs and explore new production processes to further improve the competitiveness of our production costs. In respect of commercialization, we will continue to improve the establishment of our marketing and commercialization teams while carrying out commercial cooperation with outstanding pharmaceutical companies in the global arena to continuously expand our international business layout. The Company is committed to becoming an innovative pharmaceutical company pursuing "in China, for global", integrating R&D, production and commercialization, and benefiting patients with world-class and trustworthy innovative drugs.

Financial Review

1. Revenue

As at 30 June 2024, total revenue of the Group reached approximately RMB786 million, representing an increase of approximately 17% compared to the corresponding period in 2023, which includes: (i) revenue from pharmaceutical products of approximately RMB709 million, increased by approximately 11% compared to the corresponding period in 2023, which was mainly due to approval of more indications of TUOYI®; (ii) revenue from technical services of approximately RMB52 million; and (iii) revenue from out-licensing of approximately RMB24 million. During the Reporting Period, the domestic sales revenue of TUOYI® was approximately RMB671 million, representing an increase of approximately 50% compared to the corresponding period in 2023.

2. R&D Expense

R&D expenses mainly include clinical research and technical service expenses, staff salary and welfare expenses, depreciation and amortization expenses and other operating expenses.

During the Reporting Period, R&D expenses were approximately RMB546 million, which decreased by approximately RMB402 million as compared to the corresponding period in 2023, representing a decrease of approximately 42%. R&D expenses included clinical research and technical service expenses of approximately RMB286 million, staff salary and welfare expenses of approximately RMB193 million, depreciation and amortization expenses of approximately RMB42 million and other operating expenses of approximately RMB25 million. In particular, clinical research and technical service expenses, staff salary and welfare expenses, depreciation and amortization expenses and other operating expenses decreased by approximately 54%, 16%, 34% and 2% as compared to the corresponding period in 2023, respectively. As at 31 December 2023, all expenses related to the restricted share incentive scheme of the Group were recognized, and thus no share-based payment expenses were recognized during the Reporting Period.

The decrease in R&D expenses was mainly due to (i) the Group's cost control policy and efforts to optimize resource allocation and focusing on R&D pipelines with greater potential, and (ii) natural decline of R&D expenditure as a number of clinical trials of our core product TUOYI® successively met the primary endpoints.

3. Selling and Distribution Expenses

Selling and distribution expenses mainly include staff salary and welfare expenses, expenses for marketing and promotion activities and other operating expenses.

During the Reporting Period, selling and distribution expenses amounted to approximately RMB428 million, which increased by approximately RMB54 million as compared to the corresponding period in 2023, representing an increase of approximately 15%. Selling and distribution expenses included staff salary and welfare expenses of approximately RMB236 million, expenses for marketing and promotion activities of approximately RMB175 million and other operating expenses of approximately RMB17 million. In particular, staff salary and welfare expenses and expenses for marketing and promotion activities increased by approximately 16% and 18% respectively, while other operating expenses decreased by approximately 17% as compared to the corresponding period in 2023. As at 31 December 2023, all expenses related to the restricted share incentive scheme of the Group were recognized, and thus no share-based payment expenses were recognized during the Reporting Period.

The increase in selling and distribution expenses was mainly due to additional demand for market promotion of new indications of TUOYI®, which led to the increase in marketing and promotion expenses, and staff salary and welfare expenses.

4. Administrative expenses

Administrative expenses mainly include administrative staff cost, depreciation and amortization expenses, office administration expenses and other miscellaneous expenses.

During the Reporting Period, administrative expenses amounted to approximately RMB253 million, which increased by approximately RMB11 million as compared to the corresponding period in 2023, representing an increase of approximately 4%. Administrative expenses included administrative staff cost of approximately RMB110 million, depreciation and amortization expenses of approximately RMB70 million, office administration expenses of approximately RMB54 million and other miscellaneous expenses of approximately RMB19 million. In particular, administrative staff cost, depreciation and amortization expenses and office administration expenses increased by approximately 4%, 25% and 9% respectively, while other miscellaneous expenses decreased by approximately 30% as compared to the corresponding period in 2023. As at 31 December 2023, all expenses related to the restricted share incentive scheme of the Group were recognized, and thus no share-based payment expenses were recognized during the Reporting Period.

The increase in administrative expenses was mainly due to the increase in depreciation expenses. As the construction in progress of the Group was successively transferred into fixed assets, the depreciation expenses increased accordingly.

5. Liquidity and Capital Resources

As at 30 June 2024, the aggregate balance of bank balances and cash and financial products of the Group was approximately RMB3,311 million, slightly decreased by RMB467 million compared to the balance of 31 December 2023, which ensured our cash position relatively sufficient to support the Group's development. The Group's financial products were investments with original maturities of no more than 6 months and low risk, which were with fair value of approximately RMB600 million.

During the reporting period, net cash inflow from financing activities was approximately RMB739 million, and net cash outflow from operating activities was approximately RMB869 million, and net cash outflow from investing activities was approximately RMB941 million (including cash outflow in acquisition of the financial products), resulting in a decrease of RMB1,067 million in bank balances and cash from 31 December 2023.

6. Non-IFRS Measures

To supplement the Group's consolidated financial statements which are prepared in accordance with the IFRS, the Company has provided adjusted total comprehensive expenses for the period (excluding effects from non-cash related items and one-off events which include, but not limited to, share-based payment expenses and net exchange gains or losses), as additional financial measures, which are not required by, nor presented in accordance with, the IFRS. The Company believes that the non-IFRS financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company's management and investors may benefit from referring to these non-IFRS financial measures in assessing the Group's financial performance by eliminating the impacts of certain unusual and non-recurring items that the Group does not consider indicative of the performance of the Group's business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS financial results on a stand-alone basis or as a substitute for results under the IFRS, or as being comparable to results reported or forecasted by other companies.

Non-IFRS adjusted total comprehensive expenses for the period:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
IFRS total comprehensive expense for the period	**(712,787)**	(1,163,516)
Add:		
Share-based payment expenses	**–**	16,659
Net exchange gains	**(1,063)**	(2,068)
Adjusted total comprehensive expense for the period	**(713,850)**	(1,148,925)

7. Listing on the STAR Market, Placing of H Shares, Issuance of A Shares and Use of Proceeds

As approved by the China Securities Regulatory Commission (Zheng Jian Xu Ke [2020] No. 940) (證監許可[2020]940號文), the Company issued 87,130,000 ordinary shares (A Shares) with a nominal value of RMB1.00 to the public in a public offering in July 2020 at the issue price of RMB55.50 per share to allow the Company access a more established platform in the PRC capital market. The gross proceeds amounted to approximately RMB4,836 million. After deducting issuance expenses of approximately RMB339 million in accordance with the related requirements, the net proceeds amounted to approximately RMB4,497 million. The net proceeds from the listing of A Shares have been used and will be used in accordance with the uses disclosed in the Company's A share prospectus dated 8 July 2020.

Committed investment projects	**Planned use of proceeds** *RMB'000*	**Unutilized proceeds as at 31 December 2023** *RMB'000*	**Proceeds utilized during the Reporting Period** *RMB'000*	**Utilized Proceeds as at 30 June 2024** *RMB'000*	**Unutilized Proceeds as at 30 June 2024** *RMB'000*	**Expected timeline for application of the unutilized proceeds**
Research and development projects of innovative drugs	1,200,000	–	(16)	1,216,655	–	Was fully utilized by 31 December 2022
Junshi Biotech Industrialization Lingang Project	700,000	–	–	700,000	–	Was fully utilized by 31 December 2020
Repayment of bank loans and replenishment of liquidity	800,000	–	–	824,509	–	Was fully utilized by 30 June 2022
Surplus proceeds	1,796,978	233,768	44,221	1,610,586	189,820	Expected to be fully utilized by 31 December 2024
	4,496,978*(Note 1)*	223,768*(Note 2)*	44,205*(Note 2)*	4,351,750*(Note 1)*	189,820*(Notes 1&2)*	

Notes:

1. The difference between (i) the sum of utilized proceeds and the unutilized proceeds and (ii) the net proceeds from the issuance represents bank charges, foreign exchange gains and interests generated from bank saving accounts.

2. The difference between (i) the sum of proceeds utilized during the Reporting Period and unutilized proceeds as at 30 June 2024 and (ii) unutilized proceeds as at 31 December 2023 represents bank charges, foreign exchange gains and interests generated from bank saving accounts.

On 23 June 2021, the Company completed the placing of an aggregate of 36,549,200 new H Shares (the "**Placing Shares**") under general mandate pursuant to a placing agreement dated 16 June 2021 entered into by and among the Company, J.P. Morgan Securities plc (as sole placing agent), Guotai Junan Securities (Hong Kong) Limited (as co-managers) and Caitong International Securities Co., Limited (as co-managers). The Placing Shares were issued to not less than six placees who were professional, institutional and/or other investors and who were independent of, and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**")) at a placing price of HK$70.18 per H share. The market price of the H Shares on 16 June 2021 was HK$70.65 per H share. The net cash inflow from the placing was approximately RMB2,104 million. The net proceeds from the placing were intended to be used by the Group toward the R&D of drugs and pipeline expansion, expansion of the commercialization team, domestic and overseas investment, mergers and acquisitions, and business development, and general corporate purposes. The Board considered that the placing was beneficial to the Company for the following reasons: (a) available funds would be brought by the net proceeds from the Placing for the Company's sustainable development to enhance the development and commercialized layout of potential first-in-class drugs in the international market, promote and accelerate the implementation of clinical trials of more first-in-class drugs in international multi-centers, and arrange and expand new-generation platforms and R&D technologies, to further improve the Company's competitiveness; and (b) it could expand the shareholder base of the Company, optimize the shareholding structure and further attract more international renowned investment institutions with long-term strategic values through the platform of The Stock Exchange of Hong Kong Limited. For further details of the placing, please refer to the Company's announcements dated 16 June 2021 and 23 June 2021.

As at 30 June 2024, all of the net proceeds from the placing has been utilized. The following table sets out the intended use and actual usage of the net proceeds from the placing as at 30 June 2024:

Purpose of the proceeds	**Intended use of the net proceeds** *(Approx. RMB million)*	**Unutilized proceeds as at 31 December 2023** *(Approx. RMB million)*	**Proceeds utilized during the Reporting Period** *(Approx. RMB million)*	**Proceeds utilized as at 30 June 2024** *(Approx. RMB million)*	**Unutilized proceeds as at 30 June 2024** *(Approx. RMB million)*	**Expected timeline for application of the unutilized proceeds**
R&D of drugs and pipeline expansion	815	2	2	814	–	Was fully utilized by 30 June 2024
Expansion of the commercialization team	1	–	–	1	–	Was fully utilized by 31 December 2022
Domestic and overseas investment, mergers and acquisitions & business development	285	–	–	285	–	Was fully utilized by 30 June 2022
General corporate purpose	1,003	–	–	1,000	–	Was fully utilized by 31 December 2022
	2,104(Note)	2	2	2,100(Note)	–(Note)	

Note:

The difference between (i) the sum of proceeds utilized and the unutilized proceeds and (ii) the net proceeds from the Placing represents bank charges, foreign exchange losses and interests generated from bank saving accounts.

As approved by the China Securities Regulatory Commission (Zheng Jian Xu Ke [2022] No. 2616) (證監許可[2022]2616號文), the Company issued 70,000,000 ordinary shares (A Shares) with a nominal value of RMB1.00 to 17 target subscribers (including securities investment fund management companies, securities firms, trust investment companies, finance companies, insurance institutional investors, qualified foreign institutional investors, and other domestic legal persons investors and natural persons, who/which satisfy the relevant requirements of the China Securities Regulatory Commission) on 2 December 2022 at the issue price of RMB53.95 per share. The gross proceeds amounted to approximately RMB3,777 million. After deducting issuance expenses of approximately RMB32 million in accordance with the related requirements, the net proceeds amounted to approximately RMB3,745 million. The net proceeds from the issuance of A Shares have been used and will be used in accordance with the uses disclosed in the Company's circular dated 7 March 2022, announcements dated 7 March 2022, 14 June 2022 and 30 May 2024. The market price of A Shares on 2 December 2022 was RMB61.23 per A share. The Company considered that the projects funded by the proceeds involved in the issuance of A Shares would accelerate the Company's clinical research work and promote the marketing process of relevant products in the PRC and overseas, enhance the synergy between preclinical and clinical research, and relieve tensions in R&D and operation funds of the Company to a certain extent, which are conducive to the realization of the Company's core development strategy and the sustainable and sound development of the production and operation of the Company.

Purpose of the proceeds	**Intended use of the net proceeds** *(Approx. RMB million)*	**Unutilized proceeds as at 31 December 2023** *(Approx. RMB million)*	**Proceeds utilized during the Reporting Period** *(Approx. RMB million)*	**Proceeds utilized as at 30 June 2024** *(Approx. RMB million)*	**Unutilized proceeds as at 30 June 2024** *(Approx. RMB million)*	**Expected timeline for application of the unutilized proceeds**
R&D projects of innovative drugs	3,464	3,077	146	533	2,931	Expected to be fully utilized by 31 December 2026
Shanghai Junshi Biotech headquarters and R&D base project	281	137	55	199	82	Expected to be fully utilized by 31 December 2026
	3,745	3,214	201	732	3,013	

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 JUNE 2024

	NOTES	For the six months ended 30 June	
		2024	2023
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Revenue	*3*	**786,056**	669,703
Cost of sales and services		**(210,801)**	(288,513)
Gross profit		**575,255**	381,190
Other income	*4*	**34,473**	92,153
Other gains and losses	*5*	**(17,557)**	(21,183)
Impairment losses under expected credit loss model, net of reversal		**10,416**	(1,122)
Research and development expenses		**(546,376)**	(948,599)
Selling and distribution expenses		**(427,554)**	(373,126)
Administrative expenses		**(252,599)**	(241,972)
Share of losses of joint ventures		**(8,878)**	(2,057)
Share of losses of associates		**(19,347)**	(30,249)
Finance costs		**(24,393)**	(14,548)
Other expenses		**(8,334)**	(16,320)
Loss before tax		**(684,894)**	(1,175,833)
Income tax (expense) credit	*6*	**(3,551)**	50,495
Loss for the period		**(688,445)**	(1,125,338)
Other comprehensive (expense) income for the period			
Item that will not be reclassified to profit or loss:			
Fair value loss on financial asset designated as at fair value through other comprehensive income ("FVTOCI")		**(28,050)**	(60,569)
Item that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations		**3,708**	22,391
Other comprehensive expense for the period		**(24,342)**	(38,178)
Total comprehensive expense for the period		**(712,787)**	(1,163,516)

	NOTE	For the six months ended 30 June	
		2024	2023
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Loss for the period attributable to:			
– Owners of the Company		**(645,691)**	(996,421)
– Non-controlling interests		**(42,754)**	(128,917)
		(688,445)	(1,125,338)
Total comprehensive expense for the period attributable to:			
– Owners of the Company		**(670,033)**	(1,034,599)
– Non-controlling interests		**(42,754)**	(128,917)
		(712,787)	(1,163,516)
Loss per share	*8*		
– Basic (RMB yuan)		**(0.66)**	(1.01)
– Diluted (RMB yuan)		**(0.66)**	(1.01)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2024

	NOTES	**As at 30 June 2024** ***RMB'000*** **(Unaudited)**	As at 31 December 2023 *RMB'000* (Audited)
Non-current assets			
Property, plant and equipment		**3,918,692**	3,789,409
Right-of-use assets		**436,940**	463,915
Intangible assets		**126,300**	134,417
Interests in joint ventures		**100,778**	74,656
Interests in associates		**192,807**	167,920
Deferred tax assets		**102,228**	103,396
Other assets, prepayments and other receivables		**453,896**	188,388
Other financial assets		**855,338**	890,536
		6,186,979	5,812,637
Current assets			
Inventories		**554,107**	538,053
Trade receivables	*9*	**449,904**	479,723
Other assets, prepayments and other receivables		**505,156**	744,388
Other financial assets		**600,000**	–
Restricted bank deposits		**261**	9,521
Bank balances and cash		**2,711,469**	3,778,142
		4,820,897	5,549,827
Current liabilities			
Trade and other payables	*10*	**1,299,224**	1,706,015
Income tax payable		**11,095**	18,017
Borrowings	*11*	**802,216**	539,391
Deferred income		**27,200**	2,400
Contract liabilities		**154,278**	146,298
Provisions and other liabilities		**17,625**	27,104
Lease liabilities		**19,392**	35,931
		2,331,030	2,475,156
Net current assets		**2,489,867**	3,074,671
Total assets less current liabilities		**8,676,846**	8,887,308

	NOTES	As at 30 June 2024 RMB'000 (Unaudited)	As at 31 December 2023 RMB'000 (Audited)
Non-current liabilities			
Borrowings	*11*	**1,738,310**	1,195,794
Deferred income		**149,999**	181,064
Other financial liabilities		**155,597**	152,791
Lease liabilities		**9,520**	17,451
		2,053,426	1,547,100
Net assets		**6,623,420**	7,340,208
Capital and reserves			
Share capital	*12*	**985,690**	985,690
Treasury share	*13*	**(30,892)**	(26,891)
Reserves		**5,541,990**	6,212,023
Equity attributable to owners of the Company		**6,496,788**	7,170,822
Non-controlling interests		**126,632**	169,386
Total equity		**6,623,420**	7,340,208

1. GENERAL AND BASIS OF PREPARATION

The Company was established in the People's Republic of China (the "**PRC**") on 27 December 2012 and converted into a joint stock company with limited liability in May 2015. In August 2015, the Company's domestic shares became listed on the National Equities Exchange and Quotations ("**NEEQ**") (stock code: 833330). On 24 December 2018, the Company's H shares became listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 1877). The domestic shares of the Company were delisted from NEEQ since 8 May 2020 and were converted into A shares and listed on the STAR Market of the Shanghai Stock Exchange on 15 July 2020 (stock code: 688180). The respective addresses of the registered office and principal place of business of the Company are Room 1003, Level 10, Building 2, Nos. 36 and 58, Hai Qu Road, China (Shanghai) Pilot Free Trade Zone, the PRC and 5/F, Manulife Place 348 Kwun Tong Road, Kowloon, Hong Kong.

The principal activities of the Group are mainly discovery, development and commercialisation of innovative drugs.

The condensed consolidated financial statements are presented in Renminbi ("**RMB**"), which is also the functional currency of the Company.

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard ("**IAS**") 34 Interim Financial Reporting issued by the International Accounting Standards Board ("**IASB**") as well as with the applicable disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The directors of the Company have, at the time of approving the condensed consolidated financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the condensed consolidated financial statements.

2. PRINCIPAL ACCOUNTING POLICIES AND CHANGE IN KEY SOURCES OF ESTIMATION UNCERTAINTY

2.1 Principal accounting policies

The condensed consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments, which are measured at fair value.

Other than additional/change in accounting policies resulting from application of new and amendments to IFRSs, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2024 are the same as those presented in the Group's annual financial statements for the year ended 31 December 2023.

Application of amendments to IFRSs

In the current interim period, the Group has applied the following amendments to IFRSs issued by the IASB, for the first time, which are mandatorily effective for the Group's annual period beginning on 1 January 2024 for the preparation of the Group's condensed consolidated financial statements:

Amendments to IFRS 16	Lease Liability in a Sale and Leaseback
Amendments to IAS 1	Classification of Liabilities as Current or Non-current
Amendments to IAS 1	Non-current Liabilities with Covenants
Amendments to IAS 7 and IFRS 7	Supplier Finance Arrangements

The application of the amendments to IFRSs in the current period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

2.2 Change in key sources of estimation uncertainty

Useful lives of property, plant, and equipment

Over the years, the Group has developed policies and procedures to regularly maintain and overhaul the property, plant and equipment. The Group's management is of the view that given the current conditions of property, plant and equipment, it is reasonable to revise the estimation of useful lives of property, plant and equipment in order to more objectively and fairly reflect the impact of depreciation on the Group's operating results. This revised estimation is made with reference to the useful lives of property, plant and equipment of similar nature and functions in the industry. The new estimated useful lives are listed as follow with effect from 1 January 2024:

Properties	change from 20 years to 20 to 40 years
Machinery and equipment	change from 10 years to 10 to 15 years
Vehicles	unchanged at 5 years
Furniture fixtures	unchanged at 3 to 5 years
Other equipment	change from 3 to 5 years to 3 to 10 years

The change of estimation will apply prospectively and does not require retrospective adjustment, which had no impact on the Group's financial positions and performance for prior periods.

Based on the revised useful lives, it is estimated that the annual depreciation charge for the year ending 31 December 2024 will decrease by approximately RMB47 million.

3. REVENUE AND SEGMENT INFORMATION

The Group derives its revenue from the transfer of goods and services over time and at a point in time in the following major revenue sources:

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Timing of revenue recognition		
At a point in time		
Sale of pharmaceutical products	**709,044**	641,292
Licensing income	**24,485**	–
Others	**739**	–
	734,268	641,292
Over time		
Service income	**51,788**	28,411
	786,056	669,703

For the purposes of resource allocation and assessment, the Group's management reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole. No other discrete financial information is provided other than the Group's results and financial position as a whole. Accordingly, only entity-wide disclosures are presented.

During the period ended 30 June 2024, the Group recognised sales-based royalty income amounting to RMB7,429,000 (six months ended 30 June 2023: nil) and milestone payments of RMB16,344,000 (six months ended 30 June 2023: nil) upon the achievement of certain milestone pursuant the licensing agreements.

Geographical information

The Group's operations are mainly located in the PRC and the United States of America (the "**USA**").

Information about the Group's revenue from external customers is presented based on the operating location of customers.

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
The PRC	**745,213**	630,937
The USA	**23,786**	38,766
Others	**17,057**	–
	786,056	669,703

4. OTHER INCOME

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Bank interest income	**24,454**	55,027
Government grants related to property, plant and equipment *(Note a)*	**3,214**	1,080
Other subsidies *(Note b)*	**6,805**	36,046
	34,473	92,153

Notes:

(a) Amounts represent subsidies from the PRC government specifically for the capital expenditure incurred for the acquisition of buildings situated on leasehold land in the PRC and machineries, which is recognised as income over the estimated useful life of the respective assets.

(b) Amounts mainly represent subsidies from PRC government for research and development activities, which are recognised as income upon meeting specific conditions and incentives which have no specific conditions attached to the grants.

5. OTHER GAINS AND LOSSES

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Fair value change of other financial assets measured at fair value through profits or loss ("**FVTPL**"), net	**(31,696)**	(23,532)
Exchange gains, net	**1,063**	2,068
Loss on disposal of property, plant and equipment	**(388)**	(324)
Other gain *(Note)*	**14,234**	–
Others	**(770)**	605
	(17,557)	(21,183)

Note: During the period ended 30 June 2024, the Group transferred certain rights under the license agreement to Excellmab Pte. Ltd. ("**Excellmab**") in exchange of 40% equity interest in Excellmab and recognised a gain of RMB14,234,000.

6. INCOME TAX EXPENSE (CREDIT)

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current tax		
United States Corporate Income Tax ("**CIT**")	**749**	(106,231)
Singapore Corporate Income Tax	**1,634**	–
Deferred tax	**1,168**	55,736
	3,551	(50,495)

Under the law of the PRC Enterprise Income Tax (the "**EIT Law**") and implementation regulations of the EIT Law, the basic tax rate of the Company and its PRC subsidiaries is 25% for both periods. The Company and certain PRC subsidiaries of the Group were accredited as High and New Technology Enterprises and enjoyed the reduced 15% EIT rate.

TopAlliance Biosciences Inc., a wholly-owned subsidiary of the Company, is subject to the United States California Corporate Income Tax rate of 8.84% for both periods.

During the period ended 30 June 2024, the Company is subject to a United States withholding tax on licensing income received from a US-based customer amounting to RMB743,000 and a Singapore withholding tax on licensing income received from a Singapore-based customer amounting to RMB1,634,000.

During the period ended 30 June 2023, the Company received a refund of United States CIT previously withheld on licensing income from a US-based customer amounting to RMB106,231,000.

7. DIVIDENDS

No dividends were paid, declared or proposed during the six months ended 30 June 2024 and 2023. The directors of the Company have determined that no dividend will be paid in respect of the six months ended 30 June 2024 and 2023.

8. LOSS PER SHARE

The calculation of the basic and diluted loss per share attributable to the owners of the Company is based on the following data:

Loss

	For the six months ended 30 June	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period attributable to owners of the Company for the purpose of basic and diluted loss per share	**(645,691)**	(996,421)

Number of shares

	For the six months ended 30 June	
	2024	2023
	(Unaudited)	(Unaudited)
Weighted average number of ordinary shares for the purpose of basic and diluted loss per share	**984,943,273**	985,191,620

During the period ended 30 June 2024, the Company repurchased 136,844 ordinary shares (A Shares). The weighted average number of ordinary shares for the purpose of basic loss per share for the six months ended 30 June 2024 excludes shares of treasury stock repurchased.

In February 2023, the Company issued 2,818,231 ordinary shares (A Shares) to eligible persons upon the exercise of RSUs. On 2 February 2023, the shares newly issued were registered in China Securities Depository and Clearing Corporation Limited Shanghai Branch. The weighted average number of ordinary shares for the purpose of basic earnings per share for the six months ended 30 June 2023 has been adjusted for the issuance of shares upon such exercise.

The computation of diluted loss per share for the six months ended 30 June 2024 does not assume the exercise of the Company's outstanding RSUs as this would result in a decrease in loss per share.

9. TRADE RECEIVABLES

The Group allows a normal credit period of 45 to 60 days (31 December 2023: 45 to 60 days) to its trade customers.

The following is an analysis of trade receivables by age (net of allowance for credit losses) presented based on invoice dates, which approximated the revenue recognition date, at the end of the reporting period.

	As at 30 June 2024 ***RMB'000*** **(Unaudited)**	As at 31 December 2023 *RMB'000* (Audited)
0 to 90 days	**358,558**	462,972
91 to 180 days	**2,419**	9,484
Over 180 days	**88,927**	7,267
	449,904	479,723

10. TRADE AND OTHER PAYABLES

	As at 30 June 2024 ***RMB'000*** **(Unaudited)**	As at 31 December 2023 *RMB'000* (Audited)
Trade payables		
– third parties	**246,535**	247,264
Accrued expenses in respect of		
– construction cost of properties under construction	**369,863**	479,284
– research and development expenses *(Note a)*	**328,688**	408,516
– selling and distribution expenses	**53,780**	133,997
– others	**21,041**	97,137
Payables to collaboration parties under collaboration agreements *(Note b)*	**10,050**	14,947
Salary and bonus payables	**191,851**	234,202
Other tax payables	**33,776**	41,411
Other payables	**43,640**	49,257
	1,299,224	1,706,015

Notes:

(a) Amounts include service fees payable to outsourced service providers including contract research organisations and clinical trial centres.

(b) Amounts represent payables to collaboration parties for co-development of certain pharmaceutical products.

Payment terms with suppliers are mainly with credit term of 0 to 90 days (31 December 2023: 0 to 90 days) from the time when the goods and services are received from the suppliers. The following is an aging analysis of trade payables presented based on invoice date at the end of the reporting period:

	As at 30 June 2024 ***RMB'000*** **(Unaudited)**	As at 31 December 2023 *RMB'000* (Audited)
0 to 30 days	**103,774**	60,582
31 to 60 days	**35,237**	33,363
61 to 180 days	**29,314**	72,400
Over 180 days	**78,210**	80,919
	246,535	247,264

11. BORROWINGS

	As at 30 June 2024 ***RMB'000*** **(Unaudited)**	As at 31 December 2023 *RMB'000* (Audited)
Bank borrowings		
– secured	**923,142**	868,364
– unsecured	**1,617,384**	866,821
	2,540,526	1,735,185
The maturity profile of bank borrowings is as follows:		
– within one year	**802,216**	539,391
– within a period of more than one year but not exceeding two years	**483,111**	120,135
– within a period of more than two years but not exceeding five years	**761,409**	700,751
– within a period of more than five years	**493,790**	374,908
	2,540,526	1,735,185
Less: amount due within one year shown under current liabilities	**(802,216)**	(539,391)
Amount shown under non-current liabilities	**1,738,310**	1,195,794

As at 30 June 2024, the Group's variable-rate borrowings of RMB1,573,119,000 (31 December 2023: RMB1,282,750,000) carry interest at loan prime rate minus a margin, ranging from 0.45% to 0.85% (31 December 2023: 0.45% to 0.85%) per annum.

As at 30 June 2024, the Group's fixed-rate borrowings of RMB967,407,000 (31 December 2023: RMB452,435,000) carry interest at around 1.98% to 3.40% (31 December 2023: 1.98% to 3.35%) per annum.

The Group has pledged the following assets as securities for the Group's bank borrowings at the end of reporting period:

	As at 30 June 2024 *RMB'000* (Unaudited)	As at 31 December 2023 *RMB'000* *(Audited)*
Restricted bank deposits	**–**	4,672
Property, plant and equipment	**612,492**	630,372
Right-of-use assets	**137,941**	140,683
	750,433	775,727

12. SHARE CAPITAL

	Total number of shares	Amount *RMB'000*
Registered, issued and fully paid at RMB1.0 per share:		
At 1 January 2023 (Audited)	982,871,640	982,872
Exercise of RSUs	2,818,231	2,818
At 30 June 2023 (Unaudited)	985,689,871	985,690
At 1 January 2024 (audited) and 30 June 2024 (Unaudited)	985,689,871	985,690

All the new shares rank pari passu with the existing shares of the same class in all respects.

13. TREASURY SHARE

During the period ended 30 June 2024, the Company repurchased its own ordinary shares (A Shares) through the STAR Market of the Shanghai Stock Exchange as follows:

Month of repurchase	No. of ordinary shares	Price per share Highest *RMB*	Lowest *RMB*	Aggregate consideration paid *RMB'000*
March 2024	102,459	29.35	29.21	3,001
June 2024	34,385	29.14	29.03	1,000
	136,844			4,001

As at 30 June 2024, the Group had repurchased an aggregate of 815,871 ordinary shares (A shares), including 388,445 shares repurchased in September 2023 with consideration of RMB15,030,000, and 171,266 shares repurchased in October 2023 with consideration of RMB6,905,000, and 119,316 shares repurchased in December 2023 with consideration of RMB4,956,000 and shares repurchased during the period ended 30 June 2024. They are held as treasury shares by the Group. The aggregate consideration paid includes transaction fees such as stamp duty and trading commission.

FINANCIAL STATEMENTS PREPARED UNDER CHINA ACCOUNTING STANDARDS ("CAS")

The following financial information is extracted from the Company's 2024 interim report published on the website of the Shanghai Stock Exchange, which is prepared in accordance with the PRC Generally Accepted Accounting Principles.

CONSOLIDATED BALANCE SHEET

At 30 June 2024

Unit: Yuan Currency: RMB

Item	**30 June 2024**	31 December 2023
Current assets:		
Cash and bank balances	**2,711,730,023.03**	3,788,193,376.77
Held-for-trading financial assets	**600,000,000.00**	–
Accounts receivable	**449,904,393.75**	483,226,004.74
Prepayments	**267,236,638.39**	238,897,466.48
Other receivables	**201,787,961.60**	374,008,655.77
Including: Interest receivable	**–**	–
Dividend receivable	**–**	–
Inventories	**554,106,579.98**	538,052,813.07
Non-current assets due within one year	**9,336,705.99**	8,184,311.36
Other current assets	**26,794,605.60**	140,512,460.52
Total current assets	**4,820,896,908.34**	5,571,075,088.71
Non-current assets:		
Long-term equity investments	**293,584,434.64**	242,575,715.18
Investments in other equity instruments	**56,134,213.70**	84,184,097.91
Other non-current financial assets	**799,204,148.37**	806,351,904.77
Fixed assets	**2,363,540,377.29**	2,431,855,834.52
Construction in progress	**1,525,473,513.14**	1,325,356,972.04
Right-of-use assets	**30,215,309.80**	51,367,618.58
Intangible assets	**533,024,609.63**	546,964,593.08
Long-term prepaid expenses	**10,815,836.49**	12,598,552.14
Deferred tax assets	**102,228,141.29**	103,396,116.17
Other non-current assets	**453,895,968.92**	167,140,378.23
Total non-current assets	**6,168,116,553.27**	5,771,791,782.62
Total assets	**10,989,013,461.61**	11,342,866,871.33

Item	30 June 2024	31 December 2023
Current liabilities:		
Short-term loans	**667,173,900.12**	452,435,151.72
Notes payable	**–**	4,672,296.11
Accounts payable	**1,029,956,459.95**	1,381,144,867.05
Contract liabilities	**154,278,073.67**	146,298,445.27
Payroll payable	**191,851,117.58**	234,201,628.25
Taxes payable	**36,307,882.20**	50,741,556.79
Other payables	**43,640,269.58**	37,330,788.82
Including: Interest payable	**–**	–
Dividend payable	**–**	–
Non-current liabilities due within one year	**154,434,228.40**	122,886,665.63
Other current liabilities	**8,563,217.12**	8,686,175.91
Total current liabilities	**2,286,205,148.62**	2,438,397,575.55
Non-current liabilities:		
Long-term borrowings	**1,738,309,662.32**	1,195,794,059.52
Lease liabilities	**9,519,959.85**	17,451,499.85
Provisions	**17,624,701.47**	27,104,611.58
Deferred income	**177,199,159.48**	183,463,569.04
Other non-current liabilities	**155,597,072.22**	160,045,083.81
Total non-current liabilities	**2,098,250,555.34**	1,583,858,823.80
Total liabilities	**4,384,455,703.96**	4,022,256,399.35
Owners' equity:		
Share capital	**985,689,871.00**	985,689,871.00
Capital reserves	**15,394,559,338.20**	15,394,559,338.20
Less: Treasury share	**30,892,473.08**	26,891,299.08
Other comprehensive income	**-166,409,457.44**	-142,066,958.60
Retained earnings	**-9,705,021,448.29**	-9,060,066,765.05
Total equity attributable to owners of the Company	**6,477,925,830.39**	7,151,224,186.47
Minority interests	**126,631,927.26**	169,386,285.51
Total equity attributable to owners	**6,604,557,757.65**	7,320,610,471.98
Total liabilities and equity attributable to owners	**10,989,013,461.61**	11,342,866,871.33

CONSOLIDATED INCOME STATEMENT

January-June 2024

Unit: Yuan Currency: RMB

Item	**January-June 2024**	January-June 2023
I. Total operating income	**786,056,275.43**	669,702,667.07
Including: Operating income	**786,056,275.43**	669,702,667.07
II. Total operating costs	**1,434,750,281.60**	1,772,814,913.95
Including: Operating costs	**210,419,748.58**	252,155,636.11
Taxes and surcharges	**11,611,663.96**	8,775,955.55
Selling expenses	**427,553,592.62**	373,126,850.39
Administrative expenses	**239,719,730.60**	232,304,096.15
R&D expenses	**546,376,150.47**	948,598,826.58
Financial expenses	**-930,604.63**	-42,146,450.83
Including: Interest expenses	**20,686,103.23**	12,720,671.54
Interest income	**24,453,746.85**	55,026,734.29
Add: Other gains	**10,019,476.80**	33,625,928.15
Investment gains ("-" for losses)	**-27,835,848.07**	-28,070,638.56
Including: Gains from investments in associates and joint ventures	**-28,224,879.11**	-32,305,159.11
Gains from changes in fair value ("-" for losses)	**-32,147,749.55**	-27,766,182.96
Credit impairment loss ("-" for losses)	**10,415,866.31**	-1,122,091.90
Impairment loss of assets ("-" for losses)	**-381,606.68**	-36,357,648.87
Gains from disposal of assets ("-" for losses)	**12,938,477.30**	510,895.52
III. Operating revenue ("-" for losses)	**-675,685,390.06**	-1,162,291,985.50
Add: Non-operating income	**818,405.29**	3,611,791.11
Less: Non-operating expenses	**9,290,891.21**	18,144,094.93
IV. Total profit ("-" for total losses)	**-684,157,875.98**	-1,176,824,289.32
Less: Income tax expenses	**3,551,165.51**	-50,494,762.83
V. Net profit ("-" for net losses)	**-687,709,041.49**	-1,126,329,526.49
(I) Classified by business continuity		
1. Net profit from continuous operations ("-" for net losses)	**-687,709,041.49**	-1,126,329,526.49
2. Net profit from discontinued operations ("-" for net losses)	**–**	–
(II) Classified by ownership		
1. Net profit attributable to the shareholders ("-" for net losses)	**-644,954,683.24**	-997,412,406.48
2. Profit or loss attributable to minority interests ("-" for net losses)	**-42,754,358.25**	-128,917,120.01

Item	**January-June 2024**	January-June 2023
VI. Other comprehensive income after-tax, net	**-24,342,498.84**	-38,178,177.32
(I) Other comprehensive income after-tax attributable to owners of the Company, net	**-24,342,498.84**	-38,178,177.32
1. Other comprehensive income that cannot be reclassified into profit or loss	**-28,049,884.21**	-60,568,929.61
(1) Changes arising from remeasurement of defined benefit plan	**–**	–
(2) Other comprehensive income that cannot be reclassified to profit or loss using the equity method	**–**	–
(3) Changes in fair value of investments in other equity instruments	**-28,049,884.21**	-60,568,929.61
(4) Change in fair value due to enterprise's own credit risk	**–**	–
2. Other comprehensive income that can be reclassified to profit or loss	**3,707,385.37**	22,390,752.29
(1) Other comprehensive income that can be transferred to profit or loss using the equity method	**–**	–
(2) Changes in fair value of other debt investments	**–**	–
(3) Financial assets reclassified to other comprehensive income	**–**	–
(4) Credit impairment provision for other debt investments	**–**	–
(5) Cash flow hedging reserves	**–**	–
(6) Difference arising on translation of foreign currency financial statements	**3,707,385.37**	22,390,752.29
(II) Other net comprehensive income after-tax attributable to minority shareholders	**–**	–
VII. Total comprehensive income	**-712,051,540.33**	-1,164,507,703.81
(I) Total comprehensive income attributable to owners of the Company	**-669,297,182.08**	-1,035,590,583.80
(II) Total comprehensive income attributable to minority shareholders	**-42,754,358.25**	-128,917,120.01
VIII. Earnings per share		
(I) Basic earnings per share (RMB/Share)	**-0.65**	-1.01
(II) Diluted earnings per share (RMB/Share)	**-0.65**	-1.01

CONSOLIDATED CASH FLOW STATEMENT

January-June 2024

Unit: Yuan Currency: RMB

Item	**January-June 2024**	January-June 2023
I. Cash flows from operating activities:		
Cash receipts from the sale of goods and the rendering of services	**840,718,464.86**	493,939,610.73
Receipts of tax refunds	**10,546,104.09**	129,854,553.65
Other cash receipts relating to operating activities	**15,866,444.17**	100,460,611.03
Subtotal of cash inflows from operating activities	**867,131,013.12**	724,254,775.41
Cash payments for goods purchased and services received	**883,180,593.52**	1,088,928,491.83
Cash payments to and on behalf of employees	**666,064,219.15**	657,743,224.13
Payments of various types of taxes	**43,733,104.27**	41,171,147.98
Other cash payments relating to operating activities	**139,504,767.78**	162,133,712.54
Subtotal of cash outflows from operating activities	**1,732,482,684.72**	1,949,976,576.48
Net cash flows from operating activities	**-865,351,671.60**	-1,225,721,801.07
II. Cash flows from investing activities:		
Cash receipts from recovery of investments	**250,000,000.00**	1,202,852,598.61
Cash receipts from investment income	**389,043.54**	4,234,520.55
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	**1,865,000.00**	22,123.88
Other cash receipts relating to investing activities	**24,983,805.70**	58,169,603.96
Subtotal of cash inflows from investing activities	**277,237,849.24**	1,265,278,847.00
Cash payments to acquire or construct fixed assets, intangible assets and other long-term assets	**395,713,348.07**	201,430,071.66
Cash payments to acquire investments	**830,000,000.00**	1,230,000,000.00
Subtotal of cash outflows from investing activities	**1,225,713,348.07**	1,431,430,071.66
Net cash flows from investing activities	**-948,475,498.83**	-166,151,224.66

Item	**January-June 2024**	January-June 2023
III. Cash flows from financing activities:		
Cash receipts from capital contributions	**–**	155,594,530.50
Including: cash receipts from capital contributions from minority owners of subsidiaries	**–**	3,000,000.00
Cash receipts from borrowings	**1,434,543,532.27**	214,726,408.64
Other cash receipts relating to financing activities	**3,725,476.58**	41,299,690.39
Subtotal of cash inflows from financing activities	**1,438,269,008.85**	411,620,629.53
Cash repayments of borrowings	**634,028,085.17**	116,669,118.43
Cash payments for distribution of dividends or profits or settlement of interest expenses	**33,862,165.97**	17,998,153.66
Including: payments for distribution of dividends or profits to minority owners of subsidiaries	**–**	–
Other cash payments relating to financing activities	**27,995,206.63**	53,355,135.28
Subtotal of cash outflows from financing activities	**695,885,457.77**	188,022,407.37
Net cash flows from financing activities	**742,383,551.08**	223,598,222.16
IV. Effects of exchange rate fluctuations on cash and cash equivalents	**4,770,876.49**	25,100,592.95
V. Net increase in cash and cash equivalents	**-1,066,672,742.86**	-1,143,174,210.62
Add: Opening balance of cash and cash equivalents	**3,778,142,035.88**	5,996,935,997.83
VI. Closing balance of cash and cash equivalents	**2,711,469,293.02**	4,853,761,787.21

CONSOLIDATED STATEMENT OF CHANGES IN OWNERS' EQUITY

January-June 2024

Unit: Yuan Currency: RMB

Item	January-June 2024							
	Equity attributable to owners of the Company							
	Share Capital	Capital reserves	Less: Treasury share	Other comprehensive income	Retained earnings	Subtotal	Minority interests	Total equity
I. Closing balance of the preceding year	**985,689,871.00**	**15,394,559,338.20**	**26,891,299.08**	**-142,066,958.60**	**-9,060,066,765.05**	**7,151,224,186.47**	**169,386,285.51**	**7,320,610,471.98**
Add: Changes in accounting policies	-	-	-	-	-	-	-	-
II. Balance at the beginning of year	**985,689,871.00**	**15,394,559,338.20**	**26,891,299.08**	**-142,066,958.60**	**-9,060,066,765.05**	**7,151,224,186.47**	**169,386,285.51**	**7,320,610,471.98**
III. Changes in the current period ("-" for decreases)	**-**	**-**	**4,001,174.00**	**-24,342,498.84**	**-644,954,683.24**	**-673,298,356.08**	**-42,754,358.25**	**-716,052,714.33**
(I) Total comprehensive income	-	-	-	**-24,342,498.84**	**-644,954,683.24**	**-669,297,182.08**	**-42,754,358.25**	**-712,051,540.33**
(II) Increase of capital from shareholders	-	-	**4,001,174.00**	-	-	**-4,001,174.00**	-	**-4,001,174.00**
1. Ordinary shares contributed by shareholders	-	-	-	-	-	-	-	-
2. Capital contributed by holders of other equity instruments	-	-	-	-	-	-	-	-
3. Share-based payments recognized in owners' equity	-	-	-	-	-	-	-	-
4. Others	-	-	**4,001,174.00**	-	-	**-4,001,174.00**	-	**-4,001,174.00**
IV. Balance at the end of period	**985,689,871.00**	**15,394,559,338.20**	**30,892,473.08**	**-166,409,457.44**	**-9,705,021,448.29**	**6,477,925,830.39**	**126,631,927.26**	**6,604,557,757.65**

Unit: Yuan Currency: RMB

Item	Share Capital	Capital reserves	Other comprehensive income	Retained earnings	Subtotal	Minority interests	Total equity
	January-June 2023						
	Equity attributable to owners of the Company						
I. Closing balance of the preceding year	982,871,640.00	15,345,797,913.57	-68,408,497.07	-6,776,634,904.80	9,483,626,151.70	292,834,111.52	9,776,460,263.22
Add: Changes in accounting policies	–	–	–	–	–	–	–
II. Balance at the beginning of year	982,871,640.00	15,345,797,913.57	-68,408,497.07	-6,776,634,904.80	9,483,626,151.70	292,834,111.52	9,776,460,263.22
III. Changes in the current period ("-" for decreases)	2,818,231.00	42,221,208.02	-38,178,177.32	-997,412,406.48	-990,551,144.78	-399,421.91	-990,950,566.69
(I) Total comprehensive income	–	–	-38,178,177.32	-997,412,406.48	-1,035,590,583.80	-128,917,120.01	-1,164,507,703.81
(II) Increase of capital from shareholders	2,818,231.00	42,221,208.02	–	–	45,039,439.02	128,517,698.10	173,557,137.12
1. Ordinary shares contributed by shareholders	2,818,231.00	153,593,589.50	–	–	156,411,820.50	–	156,411,820.50
2. Capital contributed by holders of other equity instruments	–	–	–	–	–	–	–
3. Share-based payments recognized in owners' equity	–	17,110,122.63	–	–	17,110,122.63	35,193.99	17,145,316.62
4. Others	–	-128,482,504.11	–	–	-128,482,504.11	128,482,504.11	–
IV. Balance at the end of period	985,689,871.00	15,388,019,121.59	-106,586,674.39	-7,774,047,311.28	8,493,075,006.92	292,434,689.61	8,785,509,696.53

SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

– In July 2024, Suzhou Union Biopharm Co., Ltd.* (蘇州眾合生物醫藥科技有限公司), a wholly-owned subsidiary of the Company, received the CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER issued by The Ireland Health Products Regulatory Authority in accordance with the relevant regulations of the EMA. According to the GMP mutual recognition system among the EU member states, the obtaining of the GMP certificate indicates that the production facilities with the certificate have met the GMP standards of the EU, which is an important entry condition for toripalimab's entry into the European market.

– In July 2024, the IND application for JS125 (a targeted histone deacetylases ("**HDACs**") inhibitor) was accepted by the NMPA.

– In July 2024, the sNDA for TUOYI® in combination with bevacizumab for the first-line treatment of unresectable or metastatic HCC was accepted by the NMPA.

– In July 2024, a positive opinion from the CHMP was obtained for the MAA of toripalimab (European trade name: LOQTORZI®), which recommends approval for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic NPC, and toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC.

– In August 2024, the sNDA for TUOYI® as the first-line treatment for unresectable or metastatic melanoma has been accepted by the NMPA.

– In August 2024, the Company's A Shares have been included in the SSE STAR Brand Name Drug Index. The index selects 30 securities of the companies listed on the STAR market with the largest market capitalization and engaged in innovative drugs as constituents, reflecting the overall performance of the securities of the companies listed on the STAR market and engaged in innovative drugs.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the Reporting Period, the Company repurchased a total of 136,844 A Shares on the Shanghai Stock Exchange, all of which have not been cancelled. Details of the A Shares repurchased are as follows:

Date of repurchase	Number of A Shares repurchased	Price per share		Aggregate amount paid
		Highest	Lowest	
		RMB	*RMB*	*RMB*
7 March 2024	102,459	29.35	29.21	2,999,988.23
19 June 2024	34,385	29.14	29.03	999,982.15

Note: The total amount paid excludes transaction fees such as stamp duty and trading commission.

Save as disclosed above, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including any sale of treasury shares) during the Reporting Period. As at 30 June 2024, the Company held 815,871 treasury shares (see the paragraph headed "Treasury Share" in Note 13 to the financial statements for details).

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS AND SUPERVISORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix C3 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Hong Kong Listing Rules**") as its own code of conduct regarding Directors' securities transactions. Having made specific enquiry with each of the Directors and supervisors of the Company, they have confirmed that they had complied with such code of conduct during the Reporting Period.

CHANGES IN THE BOARD AND THE CHIEF EXECUTIVE OFFICER DURING THE REPORTING PERIOD

During the Reporting Period, the composition of the Board of Directors and the chief executive officer changed as follows:

Dr. Li Ning – *appointed as the vice chairman of the Board on 12 January 2024, and ceased to be the general manager and chief executive officer*
Dr. Zou Jianjun – *appointed as the general manager and chief executive officer on 12 January 2024*
Dr. Li Xin – *re-designated as an executive Director from her position as a non-executive Director on 28 February 2024*
Dr. Shen Jingkang – *appointed as an independent non-executive Director on 21 June 2024*
Dr. Yang Yue – *appointed as an independent non-executive Director on 21 June 2024*
Dr. Feng Hui – *retired from his position as a non-executive Director on 21 June 2024*
Dr. Roy Steven Herbst – *retired from his position as an independent non-executive Director on 21 June 2024*
Mr. Qian Zhi – *retired from his position as an independent non-executive Director on 21 June 2024*

CORPORATE GOVERNANCE

The Board is committed to maintaining high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has applied the principles and code provisions as set out in the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 of the Hong Kong Listing Rules. The Board is of the view that, during the Reporting Period, the Company has complied with all code provisions as set out in the CG Code.

AUDIT COMMITTEE

The Audit Committee comprises two independent non-executive Directors, namely Mr. Zhang Chun (chairman of the Audit Committee) and Dr. Shen Jingkang, and one non-executive Director, namely Mr. Tang Yi. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Group and overseeing the audit process.

The Audit Committee has reviewed, together with the management and external auditors, the accounting principles and policies adopted by the Group and the condensed consolidated financial statements for the Reporting Period.

REVIEW OF INTERIM RESULTS

The interim results of the Group for the six months ended 30 June 2024 have not been audited, but have been reviewed by the Audit Committee.

INTERIM DIVIDEND

The Board does not recommend any payment of an interim dividend for the Reporting Period.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT FOR THE REPORTING PERIOD

This interim results announcement has been published on the websites of the Company (www.junshipharma.com), the Hong Kong Stock Exchange (http://www.hkexnews.hk) and the Shanghai Stock Exchange (http://www.sse.com.cn), and the interim report for the Reporting Period containing all the information required by the Hong Kong Listing Rules will be published on the respective websites of the Hong Kong Stock Exchange and the Company in due course.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 30 August 2024

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Meng Anming, Dr. Shen Jingkang and Dr. Yang Yue as independent non-executive Directors.

* *For identification purpose only*